Spinal Muscular Atrophy

Genetic MONDO:0001516 Pathograph 41 Show in embeddings browser Motor Neuron Disease Neuromuscular Disease

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by biallelic loss of the SMN1 gene, leading to deficiency of the survival motor neuron (SMN) protein and degeneration of alpha motor neurons in the anterior horn of the spinal cord. This produces progressive, symmetric proximal muscle weakness and atrophy. Disease severity, classified into types 1-4, correlates inversely with the copy number of the modifying SMN2 gene.

Ask OpenScientist

Ask a research question about Spinal Muscular Atrophy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
1
Inheritance
6
Pathophys.
35
Phenotypes
1
Hypotheses
1
Gaps
41
Pathograph
2
Genes
5
Medical Actions
4
Subtypes
1
Datasets
15
References
2
Deep Research
1
Hyp. Reports
📘

Definitions

1
Orphanet disease definition
Orphanet defines proximal spinal muscular atrophy as a group of neuromuscular disorders characterized by progressive muscle weakness resulting from the degeneration and loss of the lower motor neurons in the spinal cord and the brain stem nuclei.
CASE_DEFINITION
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"A group of neuromuscular disorders characterized by progressive muscle weakness resulting from the degeneration and loss of the lower motor neurons in the spinal cord and the brain stem nuclei."
Orphanet definition for proximal spinal muscular atrophy.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:70 SUPPORT Other
"Autosomal recessive"
Orphanet records autosomal recessive inheritance for proximal SMA.
PMID:18572081 SUPPORT Human Clinical
"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."
Lancet review confirms autosomal recessive inheritance.
◆

Subtypes

4
SMA Type 1 (Werdnig-Hoffmann) MONDO:0009669
Most severe, onset before 6 months, never sit independently, death usually by age 2.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"OMIM:253300 | Broader"
Orphanet cross-reference maps ORPHA:70 to OMIM:253300 (SMA Type 1) as a broader mapping.
SMA Type 2 MONDO:0009673
Intermediate, onset 6-18 months, can sit but never walk independently.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"OMIM:253550 | Broader"
Orphanet cross-reference maps ORPHA:70 to OMIM:253550 (SMA Type 2) as a broader mapping.
SMA Type 3 (Kugelberg-Welander) MONDO:0009672
Milder, onset after 18 months, can walk but may lose ability later.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"OMIM:253400 | Broader"
Orphanet cross-reference maps ORPHA:70 to OMIM:253400 (SMA Type 3) as a broader mapping.
SMA Type 4 MONDO:0010056
Adult onset, mildest form, normal lifespan with mild weakness.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"OMIM:271150 | Broader"
Orphanet cross-reference maps ORPHA:70 to OMIM:271150 (SMA Type 4) as a broader mapping.
◈

Mechanistic Hypotheses

1
Canonical SMN1 Deficiency / SMN Protein Loss / Motor Neuron Degeneration Model
canonical_smn1_deficiency_motor_neuron_degeneration_model CANONICAL
Spinal muscular atrophy (SMA) is caused by biallelic loss-of-function variants in SMN1 on 5q13, most commonly homozygous SMN1 exon 7 deletion. SMN1 encodes the ubiquitously expressed Survival of Motor Neuron (SMN) protein, which functions in snRNP biogenesis, axonal mRNA transport, and neuromuscular junction development. SMA severity is inversely modified by SMN2 copy number — a near-identical paralog that produces predominantly an unstable, exon-7-skipped transcript (SMN-Δ7) but generates a low level of full-length SMN. SMN deficiency selectively kills alpha motor neurons in the anterior horn of the spinal cord, producing progressive symmetric weakness, hypotonia, and respiratory failure. Three FDA-approved therapies — nusinersen (intrathecal antisense oligonucleotide enhancing SMN2 exon 7 inclusion), onasemnogene abeparvovec (AAV9-SMN1 gene therapy, single intravenous infusion), and risdiplam (oral small-molecule SMN2 splicing modifier) — definitively validate the SMN-deficiency axis as the canonical pathogenic mechanism.
Retained as CANONICAL with important scope qualifiers. The 2026 falcon hypothesis-search report (kb/hypotheses/Spinal_Muscular_Atrophy/canonical_smn1_deficiency_motor_neuron_degeneration_model; openscientist timed out at 3600s) finds SUPPORTED. The core biallelic SMN1 loss → SMN protein deficiency → motor-neuron degeneration axis is strongly validated: 226/229 patients show complete SMN1 absence; >95% have homozygous SMN1 deletions/mutations; SMN2 copy number inversely correlates with severity via the canonical ~90% exon-7 skipping rule- of-thumb. Three FDA-approved SMN-restoring therapies (nusinersen, risdiplam, onasemnogene abeparvovec) provide compelling causal validation. Two important qualifications: (1) SMA is a MULTI-SYSTEM disorder — non-neuronal involvement in skeletal muscle, heart, mitochondria, and other tissues is now documented; (2) SMN restoration is NOT FULLY REVERSIBLE — particularly when treatment is post-symptomatic, residual musculoskeletal, metabolic/mitochondrial, and possibly glial/inflammatory pathology persists. Recent syntheses broaden SMA pathogenesis from a purely motor- neuron-autonomous model to a systemic framework involving SMN's roles in snRNP biogenesis, translation, endocytosis, and cellular homeostasis. Newborn-screening + pre-symptomatic AAV9-SMN1 gene therapy yields the strongest phenotypic rescue, supporting the canonical SMN-deficiency axis but also indicating that timing within a developmental window matters more than restoration sufficiency alone.
Deep research
Falcon citations 41 citations 2026-05-25T14:01:09.601453
Show evidence (1 reference)
PMID:16364894 SUPPORT Other
"SMA is caused by mutations in a single gene, the Survival of Motor Neuron 1 (SMN1) gene."
Existing canonical mechanism citation in the dismech knowledge base, used as the seed for the hypothesis-search deep-research run.
?

Discussions and Knowledge Gaps

1
Is early microRNA accumulation in SMA (specifically miR-128-3p dysregulation) a primary pathogenic initiating event upstream of SMN-driven motor neuron degeneration, or a secondary consequence of SMN deficiency? The temporal relationship between SMN loss and microRNA dysregulation remains mechanistically unclear. Additionally, does the miR-128-3p→Hipk2 regulatory axis contribute directly to motor neuron injury, or does it represent a downstream marker of broader RNA metabolism dysfunction?
KNOWLEDGE GAP OPEN gap_sma_microrna_primary_vs_secondary
Attached to
pathophysiology#SMN Protein Deficiency pathophysiology#Motor Neuron Degeneration
The SMN1 deficiency in SMA leads to widespread disruption in RNA metabolism, including dysregulation of microRNAs. PMID:42260294 demonstrates that early microRNA accumulation in SMA mouse spinal cords can contribute to molecular dysfunctions and "may represent an initiating event in pathogenesis." However, whether microRNA dysregulation is an upstream driver of pathology or a secondary consequence of SMN loss remains unresolved. The specific miR-128-3p inhibitor was shown to interfere with flunarizine-induced neurite outgrowth in vitro, and Hipk2 was identified as a novel miR-128-3p target, suggesting a potentially druggable axis. Determining the causal vs. reactive nature of this dysregulation is critical for mechanism-based therapeutic design.
Proposed experiments
Temporal kinetics of SMN loss versus microRNA dysregulation in SMA models
temporal kinetics study with molecular markers
exp_sma_temporal_microrna_smn
Use inducible SMN degradation (degron) systems in mouse SMA models or patient-derived fibroblasts to establish the temporal relationship between SMN protein depletion and miR-128-3p accumulation. Measure SMN levels, miR-128-3p expression, Hipk2 mRNA/protein, and early neurite outgrowth markers at precise time intervals to determine whether miR-128-3p elevation precedes, follows, or is concurrent with SMN loss. If microRNA changes precede motor neuron degeneration, this would support a primary pathogenic role; if reactive, therapeutic targeting must address upstream SMN deficiency.
Model systems
Inducible SMN degradation SMA mouse model
Mouse expressing an SMN-degron fusion allowing rapid, controlled SMN depletion via doxycycline or other degron system, enabling precise temporal measurement of downstream molecular events (miR-128-3p, Hipk2, neurodevelopmental markers).
OTHER
miR-128-3p inhibition rescue of motor neuron degeneration in vivo
antisense oligonucleotide or antagomiR in vivo efficacy
exp_sma_microrna_inhibition_rescue
Test whether early inhibition of miR-128-3p (e.g., with antagomiR or ASO blocking miR-128-3p) in presymptomatic or early symptomatic SMA mouse models rescues motor neuron survival and delays disease progression independently of SMN restoration. Measure motor neuron counts, motor function (rotarod, grip strength), lifespan, and spinal miRNA levels. If miR-128-3p inhibition provides significant rescue without restoring SMN, this would indicate a primary pathogenic role; limited/no rescue would suggest secondary status.
Model systems
SMA mouse model with locked miR-128-3p inhibitor
Severe SMA mouse model (Smn1-/-; Smn2 transgene) treated with miR-128-3p antagomiR or locked nucleic acid (LNA) inhibitor delivered neonatally or in early postnatal period to assess whether miRNA inhibition alone can modify motor neuron and behavioral phenotypes.
OTHER
Hipk2-dependent vs. independent effects of miR-128-3p in motor neurons
isogenic genetic background comparison in iPSC-derived neurons
exp_sma_hipk2_axis_causality
Generate motor neurons (iPSC-derived or transgenic mouse neurons) with miR-128-3p overexpression, and compare phenotypes in isogenic Hipk2-wildtype vs. Hipk2-knockout backgrounds. If Hipk2 loss fully rescues miR-128-3p overexpression phenotypes, this indicates Hipk2 is the canonical target mediating miRNA toxicity. Evaluate neurite outgrowth, synaptic markers, and cell viability. Discordant rescue would suggest off-target effects of miR-128-3p.
Model systems
Human iPSC-derived motor neurons with miR-128-3p and Hipk2 perturbations
Motor neurons differentiated from patient-derived SMA iPSCs or gene-edited controls, with CRISPR/Cas9-mediated knockout or overexpression of miR-128-3p and Hipk2 to dissect the regulatory axis in a disease-relevant human cellular context.
IPSC DERIVED MODEL
Show evidence (1 reference)
PMID:42260294 SUPPORT Model Organism
"early microRNA accumulation in spinal cords of SMA models can contribute to molecular dysfunctions and may represent an initiating event in pathogenesis"
Mouse SMA model data demonstrating early miR-128-3p dysregulation and its contribution to molecular dysfunction.
⚙

Pathophysiology

6
SMN Protein Deficiency
Homozygous deletion or mutation of SMN1 gene causes deficiency of survival motor neuron protein. SMN2 gene produces some functional protein but mostly truncated due to exon 7 skipping. SMN protein is essential for motor neuron survival and function.
Motor Neuron CL:0000100
spliceosomal snRNP assembly GO:0000387
Downstream
Motor Neuron Degeneration Reduced SMN impairs spliceosome assembly and selectively injures alpha motor neurons.
SMN-Dependent Neurodevelopmental Disruption Early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows, affecting spinal, cortical, and cerebellar networks.
Show evidence (2 references)
PMID:16364894 SUPPORT
"SMA is caused by mutations in a single gene, the Survival of Motor Neuron 1 (SMN1) gene."
Review confirms SMN1 gene mutations cause SMA.
PMID:18572081 SUPPORT
"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion,..."
Lancet review confirms SMN1 gene disruption causes SMA with motor neuron degeneration.
Motor Neuron Degeneration
Loss of alpha motor neurons in the anterior horn of the spinal cord leads to progressive denervation of skeletal muscles. Proximal muscles are more severely affected than distal muscles.
Motor Neuron CL:0000100
Neurodegeneration GO:0008219
Downstream
Hypotonia Early denervation reduces baseline muscle tone.
Progressive Muscle Weakness Ongoing denervation and muscle atrophy cause steadily worsening weakness.
Areflexia Loss of lower motor neurons reduces deep tendon reflex arcs.
Tongue Fasciculations Chronically denervated motor units generate spontaneous discharges visible as tongue fasciculations.
Respiratory Motor Unit Failure Involvement of phrenic and intercostal motor neurons compromises ventilation.
Axial Muscle Imbalance Persistent truncal denervation produces progressive postural instability.
Skeletal Muscle Atrophy
Proximal Muscle Weakness
Dysphagia
Bulbar Palsy
Constipation Denervation and bulbar/autonomic motor dysfunction can impair gastrointestinal motility.
Gastroesophageal Reflux Bulbar and respiratory motor-unit weakness predisposes to reflux and related feeding dysfunction.
Inability to Walk
Difficulty Climbing Stairs
Fatigue
Flexion Contracture
Gait Disturbance
Poor Suck
Distal Muscle Weakness
Axial Muscle Weakness
Quadriceps Muscle Weakness
Weakness of Facial Musculature
Difficulty Running
Triceps Weakness
Show evidence (1 reference)
PMID:16364894 SUPPORT
"The disease results in motor neuron loss and skeletal muscle atrophy."
Review confirms motor neuron loss as the pathological basis of SMA.
Respiratory Motor Unit Failure
Denervation of diaphragm and intercostal muscles reduces tidal volume, cough strength, and airway clearance, predisposing to respiratory decompensation.
Downstream
Respiratory Failure Progressive ventilatory muscle weakness culminates in chronic or acute respiratory failure.
Recurrent Aspiration Pneumonia
Respiratory Insufficiency Due to Muscle Weakness
Intercostal Muscle Weakness
Neonatal Respiratory Distress
Axial Muscle Imbalance
Asymmetric weakness of paraspinal and truncal muscles during growth leads to progressive spinal curvature.
Downstream
Scoliosis Chronic axial weakness and imbalance drives neuromuscular scoliosis.
Hip Dislocation
SMN-Dependent Neurodevelopmental Disruption
SMN deficiency during critical developmental windows disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions beyond the motor system. These disturbances affect cortical and cerebellar networks, conferring vulnerability to higher-order brain functions including cognition, expressive language, executive function, social communication, and behavioral regulation. Even with early disease-modifying therapy, developmental constraints and limited plasticity of specific neural circuits can leave persistent neurodevelopmental vulnerabilities.
Neural progenitor cell CL:0011020 Pyramidal neuron CL:0000598 Purkinje cell CL:0000121
Neurogenesis GO:0022008 ↓ DECREASED Synaptic transmission GO:0007268 ↓ DECREASED Axonogenesis GO:0007409 ↓ DECREASED
Downstream
Neurodevelopmental Vulnerability Early disrupted neurodevelopment confers persistent cognitive, language, executive, behavioral, and social communication vulnerability.
Expressive Language Delay Language-relevant neural circuits in cortex are vulnerable to developmental SMN deficiency.
Executive Dysfunction Disrupted synaptic development and circuit assembly affect executive-control networks.
Social Communication Vulnerability Neurodevelopmental disruption contributes to social communication vulnerabilities in treated SMA.
Global Developmental Delay
Autism Spectrum Manifestations
Show evidence (2 references)
PMID:42189425 SUPPORT Model Organism
"Evidence from experimental models demonstrates that early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows. These disturbances affect not only spinal motor circuits but also broader..."
Review synthesizes model evidence that SMN deficiency disrupts neurodevelopment across multiple CNS circuits beyond motor neurons.
PMID:42189425 SUPPORT Human Clinical
"In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous. Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly..."
Human clinical observations in the DMT era support persistent, domain-specific neurodevelopmental vulnerabilities despite early treatment.
Neuron-Glia Interactions
SMN deficiency impairs communication between neurons and glial cells (astrocytes, oligodendrocytes, microglia), disrupting myelin formation, metabolic support, and immune homeostasis during critical developmental periods.
Astrocyte CL:0000127 Oligodendrocyte CL:0000128 Microglial cell CL:0000129
Myelination GO:0022010 ↓ DECREASED Neuroinflammation GO:0006954 ↑ INCREASED
Downstream
Neurodevelopmental Vulnerability Disrupted neuron-glia support during developmental windows contributes to persistent neurodevelopmental vulnerability.
Executive Dysfunction Altered myelination and inflammatory signaling can affect circuits supporting executive control.
Show evidence (1 reference)
PMID:42189425 SUPPORT Model Organism
"Evidence from experimental models demonstrates that early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows."
Review identifies neuron-glia interactions as a key mechanism disrupted by SMN deficiency during development.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Spinal Muscular Atrophy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

35
Digestive 4
Dysphagia FREQUENT Dysphagia HP:0002015
Orphanet classifies dysphagia as frequent (79-30%); swallowing difficulties are common especially in severe types.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002015 | Dysphagia | Frequent (79-30%)"
Orphanet lists dysphagia as a frequent phenotype of proximal SMA.
Constipation OCCASIONAL Constipation HP:0002019
Orphanet classifies constipation as occasional (29-5%); due to reduced abdominal muscle tone and immobility.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002019 | Constipation | Occasional (29-5%)"
Orphanet lists constipation as an occasional phenotype of proximal SMA.
Gastroesophageal Reflux OCCASIONAL Gastroesophageal reflux HP:0002020
Orphanet classifies gastroesophageal reflux as occasional (29-5%).
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002020 | Gastroesophageal reflux | Occasional (29-5%)"
Orphanet lists gastroesophageal reflux as an occasional phenotype of proximal SMA.
Poor Suck FREQUENT Poor suck HP:0002033
Orphanet classifies poor suck as frequent (79-30%); particularly relevant in SMA types 1 and 2.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002033 | Poor suck | Frequent (79-30%)"
Orphanet lists poor suck as a frequent phenotype of proximal SMA.
Head and Neck 1
Weakness of Facial Musculature FREQUENT Weakness of facial musculature HP:0030319
Orphanet classifies weakness of facial musculature as frequent (79-30%).
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0030319 | Weakness of facial musculature | Frequent (79-30%)"
Orphanet lists weakness of facial musculature as a frequent phenotype of proximal SMA.
Musculoskeletal 8
Hypotonia OCCASIONAL Hypotonia HP:0001252
Floppy infant presentation in severe forms; Orphanet rates occasional across the full proximal SMA spectrum (very frequent in Type 1, mild/absent in Types 3-4).
Show evidence (2 references)
PMID:18572081 SUPPORT
"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."
Lancet review confirms generalized weakness as a characteristic of SMA, presenting as hypotonia in infants.
ORPHA:70 SUPPORT Other
"HP:0001252 | Hypotonia | Occasional (29-5%)"
Orphanet lists hypotonia as an occasional phenotype of proximal SMA.
Progressive Muscle Weakness VERY_FREQUENT Progressive muscle weakness HP:0003323
Symmetric, proximal greater than distal
Show evidence (1 reference)
PMID:16364894 SUPPORT
"The disease results in motor neuron loss and skeletal muscle atrophy."
Review confirms skeletal muscle atrophy (weakness) as a direct result of motor neuron loss in SMA.
Scoliosis OCCASIONAL Scoliosis HP:0002650
Progressive spinal curvature due to paraspinal muscle weakness; Orphanet rates occasional across the full proximal SMA spectrum.
Show evidence (2 references)
PMID:16364894 SUPPORT
"The disease results in motor neuron loss and skeletal muscle atrophy."
Progressive muscle weakness including paraspinal muscles leads to scoliosis in SMA patients.
ORPHA:70 SUPPORT Other
"HP:0002650 | Scoliosis | Occasional (29-5%)"
Orphanet lists scoliosis as an occasional phenotype of proximal SMA.
Skeletal Muscle Atrophy VERY_FREQUENT Skeletal muscle atrophy HP:0003202
Orphanet classifies skeletal muscle atrophy as very frequent (99-80%) in proximal SMA.
Show evidence (2 references)
ORPHA:70 SUPPORT Other
"HP:0003202 | Skeletal muscle atrophy | Very frequent (99-80%)"
Orphanet lists skeletal muscle atrophy as very frequent in proximal SMA.
PMID:16364894 SUPPORT Human Clinical
"The disease results in motor neuron loss and skeletal muscle atrophy."
Review confirms skeletal muscle atrophy as a core feature of SMA.
Proximal Muscle Weakness VERY_FREQUENT Proximal muscle weakness HP:0003701
Orphanet classifies proximal muscle weakness as very frequent (99-80%) in proximal SMA.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0003701 | Proximal muscle weakness | Very frequent (99-80%)"
Orphanet lists proximal muscle weakness as very frequent in proximal SMA.
Respiratory Insufficiency Due to Muscle Weakness FREQUENT Respiratory insufficiency due to muscle weakness HP:0002747
Orphanet classifies respiratory insufficiency due to muscle weakness as frequent (79-30%).
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002747 | Respiratory insufficiency due to muscle weakness | Frequent (79-30%)"
Orphanet lists respiratory insufficiency due to muscle weakness as a frequent phenotype of proximal SMA.
Flexion Contracture OCCASIONAL Flexion contracture HP:0001371
Orphanet classifies flexion contracture as occasional (29-5%); develops secondary to chronic immobility and muscle weakness.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0001371 | Flexion contracture | Occasional (29-5%)"
Orphanet lists flexion contracture as an occasional phenotype of proximal SMA.
Distal Muscle Weakness FREQUENT Distal muscle weakness HP:0002460
Orphanet classifies distal muscle weakness as frequent (79-30%); proximal weakness predominates but distal involvement occurs.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002460 | Distal muscle weakness | Frequent (79-30%)"
Orphanet lists distal muscle weakness as a frequent phenotype of proximal SMA.
Nervous System 4
Areflexia FREQUENT Areflexia HP:0001284
Absent deep tendon reflexes
Show evidence (2 references)
PMID:18572081 SUPPORT
"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."
Motor neuron degeneration leads to loss of deep tendon reflexes (areflexia).
ORPHA:70 SUPPORT Other
"HP:0001284 | Areflexia | Frequent (79-30%)"
Orphanet lists areflexia as a frequent phenotype of proximal SMA.
Gait Disturbance FREQUENT Gait disturbance HP:0001288
Orphanet classifies gait disturbance as frequent (79-30%); characteristic waddling gait in ambulatory SMA patients.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0001288 | Gait disturbance | Frequent (79-30%)"
Orphanet lists gait disturbance as a frequent phenotype of proximal SMA.
Global Developmental Delay OCCASIONAL Global developmental delay HP:0001263
Subtle neurodevelopmental vulnerabilities persist even with early DMT treatment. Pre-DMT studies reported preserved cognition but were shaped by survival bias and motor-dependent assessment tools. Contemporary studies reveal heterogeneous outcomes with recognition of higher-order brain function involvement.
Show evidence (1 reference)
PMID:42189425 SUPPORT Human Clinical
"Pre-DMT clinical studies reporting preserved cognition were shaped by survival bias, motor-dependent assessment tools, and limited evaluation of non-motor domains. In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and..."
Review demonstrates that neurodevelopmental vulnerability is a core feature of SMA even in the DMT era, affecting cognition, language, and behavior beyond motor function.
Autism Spectrum Manifestations OCCASIONAL Autistic behavior HP:0000729
Social communication and behavioral phenotypes reflect the broader neurodevelopmental impact of SMN deficiency beyond motor neuron pathology, particularly affecting social and communicative domains.
Show evidence (1 reference)
PMID:42189425 SUPPORT Human Clinical
"Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals. These findings align with biological constraints imposed by developmental timing and limited plasticity of specific..."
SMN-dependent disruption of cortical and cerebellar networks confers vulnerability to social and communicative development even with early intervention.
Respiratory 2
Respiratory Failure OCCASIONAL Respiratory failure HP:0002878
Leading cause of death in SMA types 1 and 2; Orphanet rates occasional across the full proximal SMA spectrum.
Show evidence (2 references)
PMID:29091570 SUPPORT
"the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005)."
ENDEAR trial uses permanent assisted ventilation as a primary endpoint, confirming respiratory failure as a key clinical outcome in infantile SMA.
ORPHA:70 SUPPORT Other
"HP:0002878 | Respiratory failure | Occasional (29-5%)"
Orphanet lists respiratory failure as an occasional phenotype of proximal SMA.
Neonatal Respiratory Distress FREQUENT Neonatal respiratory distress HP:0002643
Orphanet classifies neonatal respiratory distress as frequent (79-30%); particularly in SMA type 1 infants.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002643 | Neonatal respiratory distress | Frequent (79-30%)"
Orphanet lists neonatal respiratory distress as a frequent phenotype of proximal SMA.
Constitutional 1
Fatigue FREQUENT Fatigue HP:0012378
Orphanet classifies fatigue as frequent (79-30%).
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0012378 | Fatigue | Frequent (79-30%)"
Orphanet lists fatigue as a frequent phenotype of proximal SMA.
Other 15
Tongue Fasciculations FREQUENT Tongue fasciculations HP:0001308
Tongue fasciculations are particularly characteristic of SMA and a key clinical diagnostic sign.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0001308 | Tongue fasciculations | Frequent (79-30%)"
Orphanet lists tongue fasciculations as a frequent phenotype of proximal SMA.
Bulbar Palsy FREQUENT Bulbar palsy HP:0001283
Orphanet classifies bulbar palsy as frequent (79-30%); bulbar motor neuron involvement causes feeding and speech difficulties.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0001283 | Bulbar palsy | Frequent (79-30%)"
Orphanet lists bulbar palsy as a frequent phenotype of proximal SMA.
Recurrent Aspiration Pneumonia FREQUENT Recurrent aspiration pneumonia HP:0002100
Orphanet classifies recurrent aspiration pneumonia as frequent (79-30%); dysphagia and weak cough predispose to aspiration.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002100 | Recurrent aspiration pneumonia | Frequent (79-30%)"
Orphanet lists recurrent aspiration pneumonia as a frequent phenotype of proximal SMA.
Inability to Walk FREQUENT Inability to walk HP:0002540
Orphanet classifies inability to walk as frequent (79-30%); SMA types 1 and 2 patients are typically non-ambulatory.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002540 | Inability to walk | Frequent (79-30%)"
Orphanet lists inability to walk as a frequent phenotype of proximal SMA.
Intercostal Muscle Weakness FREQUENT Intercostal muscle weakness HP:0004878
Orphanet classifies intercostal muscle weakness as frequent (79-30%); contributes to paradoxical breathing pattern.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0004878 | Intercostal muscle weakness | Frequent (79-30%)"
Orphanet lists intercostal muscle weakness as a frequent phenotype of proximal SMA.
Difficulty Climbing Stairs FREQUENT Difficulty climbing stairs HP:0003551
Orphanet classifies difficulty climbing stairs as frequent (79-30%); hallmark of proximal weakness in ambulatory SMA patients.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0003551 | Difficulty climbing stairs | Frequent (79-30%)"
Orphanet lists difficulty climbing stairs as a frequent phenotype of proximal SMA.
Hip Dislocation OCCASIONAL Hip dislocation HP:0002827
Orphanet classifies hip dislocation as occasional (29-5%); secondary to muscle weakness and contractures.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0002827 | Hip dislocation | Occasional (29-5%)"
Orphanet lists hip dislocation as an occasional phenotype of proximal SMA.
Axial Muscle Weakness FREQUENT Axial muscle weakness HP:0003327
Orphanet classifies axial muscle weakness as frequent (79-30%); contributes to head lag and truncal instability.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0003327 | Axial muscle weakness | Frequent (79-30%)"
Orphanet lists axial muscle weakness as a frequent phenotype of proximal SMA.
Quadriceps Muscle Weakness FREQUENT Quadriceps muscle weakness HP:0003731
Orphanet classifies quadriceps muscle weakness as frequent (79-30%).
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0003731 | Quadriceps muscle weakness | Frequent (79-30%)"
Orphanet lists quadriceps muscle weakness as a frequent phenotype of proximal SMA.
Difficulty Running FREQUENT Difficulty running HP:0009046
Orphanet classifies difficulty running as frequent (79-30%); early sign in ambulatory SMA patients.
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0009046 | Difficulty running | Frequent (79-30%)"
Orphanet lists difficulty running as a frequent phenotype of proximal SMA.
Triceps Weakness FREQUENT Triceps weakness HP:0031108
Orphanet classifies triceps weakness as frequent (79-30%).
Show evidence (1 reference)
ORPHA:70 SUPPORT Other
"HP:0031108 | Triceps weakness | Frequent (79-30%)"
Orphanet lists triceps weakness as a frequent phenotype of proximal SMA.
Neurodevelopmental Vulnerability OCCASIONAL Neurodevelopmental abnormality HP:0012759
In the disease-modifying therapy (DMT) era, presymptomatic treatment has improved developmental outcomes; however, subtle cognitive, language, behavioral, executive function, and social communication vulnerabilities remain heterogeneous even among optimally treated individuals. These vulnerabilities reflect biological constraints imposed by developmental timing and limited plasticity of specific neural circuits affected by early SMN deficiency.
Show evidence (2 references)
PMID:42189425 SUPPORT Human Clinical
"In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous. Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly..."
Review documents persistent, domain-specific neurodevelopmental vulnerabilities in optimally treated SMA without implying broad global developmental delay.
PMID:42189425 SUPPORT Human Clinical
"These findings align with biological constraints imposed by developmental timing and limited plasticity of specific neural circuits."
Review links persistent vulnerabilities to developmental timing and limited plasticity after early SMN deficiency.
Expressive Language Delay Expressive language delay HP:0002474
Subtle expressive language vulnerabilities are increasingly recognized in DMT-treated individuals, reflecting developmental constraints of language-relevant neural circuits vulnerable to SMN deficiency.
Show evidence (1 reference)
PMID:42189425 SUPPORT Human Clinical
"Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
Contemporary evidence shows expressive language delay as a recognized phenotype of SMA in the treatment era, reflecting the broader neurodevelopmental impact of SMN deficiency.
Executive Dysfunction OCCASIONAL Impaired executive functioning HP:0033051
Deficits in executive function represent a subtle neurodevelopmental vulnerability persisting despite improved motor outcomes with DMT.
Show evidence (1 reference)
PMID:42189425 SUPPORT Human Clinical
"Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
Review identifies executive dysfunction as a neurodevelopmental outcome of early SMN deficiency affecting higher-order brain functions.
Social Communication Vulnerability Abnormal social behavior HP:0012433
Social communication vulnerabilities are increasingly recognized in DMT-treated individuals as part of the broader non-motor neurodevelopmental phenotype.
Show evidence (1 reference)
PMID:42189425 SUPPORT Human Clinical
"Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
Review explicitly identifies social communication as a neurodevelopmental vulnerability in DMT-treated SMA.
🧬

Genetic Associations

2
SMN1 (Causative)
Show evidence (1 reference)
PMID:18572081 SUPPORT
"It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation."
Lancet review confirms SMN1 gene disruption is the causative mechanism of SMA.
SMN2 (Modifier)
💊

Medical Actions

5
Nusinersen (Spinraza)
Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration.
Show evidence (2 references)
PMID:29091570 SUPPORT
"Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group."
ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA.
PMID:29091570 SUPPORT
"Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein."
NEJM paper confirms mechanism of action of nusinersen.
Onasemnogene abeparvovec (Zolgensma)
AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion.
Show evidence (1 reference)
PMID:35715567 SUPPORT
"Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention."
SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants.
Risdiplam (Evrysdi)
Oral small molecule SMN2 splicing modifier, daily oral administration.
Show evidence (1 reference)
PMID:34320287 SUPPORT
"In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts."
FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA.
Supportive Care
Respiratory support, nutritional management, physical therapy, orthopedic interventions.
Multidisciplinary Care and Rehabilitation Management (2018 SMA Care Group, Part 1)
Action: supportive care MAXO:0000950
The 2018 SMA Care Group consensus update provides evidence-based recommendations for diagnosis, rehabilitation, orthopedic and spinal management, and nutritional, swallowing and gastrointestinal care across SMA subtypes. It updates the 2007 International Conference on the Standard of Care for SMA, the foundational global consensus, with Part 2 separately addressing pulmonary and acute management.
Show evidence (3 references)
PMID:29290580 SUPPORT Human Clinical
"In 2007, an International Conference on the Standard of Care for SMA published a consensus statement on SMA standard of care that has been widely used throughout the world. Here we report a two-part update of the topics covered in the previous recommendations."
Establishes this document as the formal 2018 update to the 2007 globally adopted SMA standard-of-care consensus.
PMID:29290580 SUPPORT Human Clinical
"an update on diagnosis, rehabilitation, orthopedic and spinal management; and nutritional, swallowing and gastrointestinal management"
Defines the four care domains covered in Part 1: rehabilitation, orthopedic/spinal, and nutritional/gastrointestinal management across SMA subtypes.
PMID:29290580 SUPPORT Human Clinical
"Pulmonary management, acute care, other organ involvement, ethical issues, medications, and the impact of new treatments for SMA are discussed in part 2."
Documents the full multisystem scope of the two-part consensus update; pulmonary and acute care are addressed in the companion Part 2 document.
🔬

Biochemical Markers

1
Creatine Kinase (Normal or mildly elevated)
Context: Unlike muscular dystrophies, CK is typically normal or only mildly elevated
📊

Related Datasets

1
Transcriptome profiling of severe spinal muscular atrophy mouse embryonic stem cell-derived motor neurons geo:GSE56284
RNA-seq profiling of mouse embryonic stem cell-derived motor neurons from SMA model and control lines.
mouse BULK RNA SEQ n=6
motor neuron CL:0000100
Conditions: SMA mouse model control
D7 Hb9:GFP mESC-derived motor neurons from SMA and control lines.
{ }

Source YAML

click to show 
name: Spinal Muscular Atrophy
creation_date: '2026-01-07T17:31:51Z'
updated_date: '2026-04-28T00:00:00Z'
description: >-
  Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder
  caused by biallelic loss of the SMN1 gene, leading to deficiency of the survival
  motor neuron (SMN) protein and degeneration of alpha motor neurons in the
  anterior horn of the spinal cord. This produces progressive, symmetric proximal
  muscle weakness and atrophy. Disease severity, classified into types 1-4,
  correlates inversely with the copy number of the modifying SMN2 gene.
category: Genetic
parents:
- Motor Neuron Disease
- Neuromuscular Disease
disease_term:
  preferred_term: spinal muscular atrophy
  term:
    id: MONDO:0001516
    label: spinal muscular atrophy
definitions:
- name: Orphanet disease definition
  definition_type: CASE_DEFINITION
  description: >
    Orphanet defines proximal spinal muscular atrophy as a group of neuromuscular
    disorders characterized by progressive muscle weakness resulting from the
    degeneration and loss of the lower motor neurons in the spinal cord and the
    brain stem nuclei.
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A group of neuromuscular disorders characterized by progressive muscle weakness resulting from the degeneration and loss of the lower motor neurons in the spinal cord and the brain stem nuclei."
    explanation: Orphanet definition for proximal spinal muscular atrophy.
external_assertions:
- name: Orphanet Proximal spinal muscular atrophy record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:70
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=70
  description: >
    Orphanet identifies proximal spinal muscular atrophy as ORPHA:70 and provides
    exact cross-references including MONDO:0019079 and UMLS:C4024957.
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0019079 | Exact"
    explanation: Orphanet cross-reference table maps ORPHA:70 exactly to MONDO:0019079.
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UMLS:C4024957 | Exact"
    explanation: Orphanet cross-reference table maps ORPHA:70 exactly to UMLS C4024957.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet records autosomal recessive inheritance for proximal SMA.
  - reference: PMID:18572081
    reference_title: "Spinal muscular atrophy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."
    explanation: Lancet review confirms autosomal recessive inheritance.
has_subtypes:
- name: SMA Type 1 (Werdnig-Hoffmann)
  description: Most severe, onset before 6 months, never sit independently, death usually by age 2.
  subtype_term:
    preferred_term: spinal muscular atrophy, type 1
    term:
      id: MONDO:0009669
      label: spinal muscular atrophy, type 1
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:253300 | Broader"
    explanation: Orphanet cross-reference maps ORPHA:70 to OMIM:253300 (SMA Type 1) as a broader mapping.
- name: SMA Type 2
  description: Intermediate, onset 6-18 months, can sit but never walk independently.
  subtype_term:
    preferred_term: spinal muscular atrophy, type II
    term:
      id: MONDO:0009673
      label: spinal muscular atrophy, type II
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:253550 | Broader"
    explanation: Orphanet cross-reference maps ORPHA:70 to OMIM:253550 (SMA Type 2) as a broader mapping.
- name: SMA Type 3 (Kugelberg-Welander)
  description: Milder, onset after 18 months, can walk but may lose ability later.
  subtype_term:
    preferred_term: spinal muscular atrophy, type III
    term:
      id: MONDO:0009672
      label: spinal muscular atrophy, type III
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:253400 | Broader"
    explanation: Orphanet cross-reference maps ORPHA:70 to OMIM:253400 (SMA Type 3) as a broader mapping.
- name: SMA Type 4
  description: Adult onset, mildest form, normal lifespan with mild weakness.
  subtype_term:
    preferred_term: spinal muscular atrophy, type IV
    term:
      id: MONDO:0010056
      label: spinal muscular atrophy, type IV
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:271150 | Broader"
    explanation: Orphanet cross-reference maps ORPHA:70 to OMIM:271150 (SMA Type 4) as a broader mapping.
prevalence:
- population: United States modeled prevalence and published birth-prevalence literature
  percentage: approximately 9,429 people living with SMA in the United States
  notes: >-
    The same analysis used a reported SMA genotype birth prevalence range of
    8.5-10.3 per 100,000 live births, with a mid-range estimate of 9.4 per
    100,000 live births.
  evidence:
  - reference: PMID:29183396
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The reported estimates of SMA genotype prevalence at birth consistently range from 8.5-10.3 per 100,000 live births, with a mid-range estimate of 9.4 per 100,000.
    explanation: >-
      This literature-based modeling study summarizes the reported SMA birth
      prevalence range used to estimate population burden.
  - reference: PMID:29183396
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We estimated the number of prevalent cases in the US to be 8526, 9429, and 10,333 based on a birth prevalence of 8.5, 9.4, and 10.3, respectively (the lower, midpoint, and upper ends of the reported range).
    explanation: >-
      This provides a modeled estimate of the number of people living with SMA
      in the United States at the commonly cited midpoint birth-prevalence
      assumption.
- population: Europe (Orphanet annual incidence)
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: "1-9 / 100 000"
  notes: Orphanet reports a European annual incidence class of 1-9 per 100,000.
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Annual incidence | INST"
    explanation: Orphanet epidemiology table provides the annual incidence class for proximal SMA in Europe.
- population: Europe (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: "1-9 / 100 000"
  notes: Orphanet reports a European point-prevalence class of 1-9 per 100,000.
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Europe | Point prevalence | ORPHANET"
    explanation: Orphanet epidemiology table provides the point prevalence class for proximal SMA in Europe.
- population: Europe (Orphanet prevalence at birth)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: "1-5 / 10 000"
  notes: Orphanet reports a European prevalence at birth class of 1-5 per 10,000, citing PMID:23107878.
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Europe | Prevalence at birth | PMID:23107878"
    explanation: Orphanet epidemiology table provides the prevalence at birth class for proximal SMA in Europe.
progression:
- phase: Onset
  age_range: All ages
  notes: Orphanet records onset across all ages; SMA type 1 presents before 6 months, type 2 at 6-18 months, type 3 after 18 months, and type 4 in adulthood.
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet records all ages as the age-of-onset category for proximal SMA.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_smn1_deficiency_motor_neuron_degeneration_model
  hypothesis_label: Canonical SMN1 Deficiency / SMN Protein Loss / Motor Neuron Degeneration Model
  status: CANONICAL
  description: >-
    Spinal muscular atrophy (SMA) is caused by biallelic loss-of-function variants in SMN1 on 5q13, most
    commonly homozygous SMN1 exon 7 deletion. SMN1 encodes the ubiquitously expressed Survival of Motor
    Neuron (SMN) protein, which functions in snRNP biogenesis, axonal mRNA transport, and neuromuscular
    junction development. SMA severity is inversely modified by SMN2 copy number — a near-identical
    paralog that produces predominantly an unstable, exon-7-skipped transcript (SMN-Δ7) but generates a
    low level of full-length SMN. SMN deficiency selectively kills alpha motor neurons in the anterior
    horn of the spinal cord, producing progressive symmetric weakness, hypotonia, and respiratory
    failure. Three FDA-approved therapies — nusinersen (intrathecal antisense oligonucleotide enhancing
    SMN2 exon 7 inclusion), onasemnogene abeparvovec (AAV9-SMN1 gene therapy, single intravenous
    infusion), and risdiplam (oral small-molecule SMN2 splicing modifier) — definitively validate the
    SMN-deficiency axis as the canonical pathogenic mechanism.
  notes: >-
    Retained as CANONICAL with important scope qualifiers.
    The 2026 falcon hypothesis-search report
    (kb/hypotheses/Spinal_Muscular_Atrophy/canonical_smn1_deficiency_motor_neuron_degeneration_model;
    openscientist timed out at 3600s) finds SUPPORTED. The core
    biallelic SMN1 loss → SMN protein deficiency → motor-neuron
    degeneration axis is strongly validated: 226/229 patients
    show complete SMN1 absence; >95% have homozygous SMN1
    deletions/mutations; SMN2 copy number inversely correlates
    with severity via the canonical ~90% exon-7 skipping rule-
    of-thumb. Three FDA-approved SMN-restoring therapies
    (nusinersen, risdiplam, onasemnogene abeparvovec) provide
    compelling causal validation. Two important qualifications:
    (1) SMA is a MULTI-SYSTEM disorder — non-neuronal involvement
    in skeletal muscle, heart, mitochondria, and other tissues
    is now documented; (2) SMN restoration is NOT FULLY
    REVERSIBLE — particularly when treatment is post-symptomatic,
    residual musculoskeletal, metabolic/mitochondrial, and
    possibly glial/inflammatory pathology persists. Recent
    syntheses broaden SMA pathogenesis from a purely motor-
    neuron-autonomous model to a systemic framework involving
    SMN's roles in snRNP biogenesis, translation, endocytosis,
    and cellular homeostasis. Newborn-screening + pre-symptomatic
    AAV9-SMN1 gene therapy yields the strongest phenotypic
    rescue, supporting the canonical SMN-deficiency axis but
    also indicating that timing within a developmental window
    matters more than restoration sufficiency alone.
  evidence:
  - reference: PMID:16364894
    reference_title: "Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SMA is caused by mutations in a single gene, the Survival of Motor Neuron 1 (SMN1) gene."
    explanation: >
      Existing canonical mechanism citation in the dismech
      knowledge base, used as the seed for the hypothesis-search
      deep-research run.
pathophysiology:
- name: SMN Protein Deficiency
  description: >
    Homozygous deletion or mutation of SMN1 gene causes deficiency of survival motor
    neuron protein.
    SMN2 gene produces some functional protein but mostly truncated due to exon 7
    skipping.
    SMN protein is essential for motor neuron survival and function.
  cell_types:
  - preferred_term: Motor Neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: spliceosomal snRNP assembly
    term:
      id: GO:0000387
      label: spliceosomal snRNP assembly
  evidence:
  - reference: PMID:16364894
    reference_title: "Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease."
    supports: SUPPORT
    snippet: "SMA is caused by mutations in a single gene, the Survival of Motor Neuron 1 (SMN1) gene."
    explanation: Review confirms SMN1 gene mutations cause SMA.
  - reference: PMID:18572081
    reference_title: "Spinal muscular atrophy."
    supports: SUPPORT
    snippet: "Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation."
    explanation: Lancet review confirms SMN1 gene disruption causes SMA with motor neuron degeneration.
  downstream:
  - target: Motor Neuron Degeneration
    description: Reduced SMN impairs spliceosome assembly and selectively injures alpha motor neurons.
  - target: SMN-Dependent Neurodevelopmental Disruption
    description: Early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows, affecting spinal, cortical, and cerebellar networks.
- name: Motor Neuron Degeneration
  description: >
    Loss of alpha motor neurons in the anterior horn of the spinal cord leads to
    progressive denervation of skeletal muscles. Proximal muscles are more severely
    affected than distal muscles.
  cell_types:
  - preferred_term: Motor Neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: Neurodegeneration
    term:
      id: GO:0008219
      label: cell death
  evidence:
  - reference: PMID:16364894
    reference_title: "Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease."
    supports: SUPPORT
    snippet: "The disease results in motor neuron loss and skeletal muscle atrophy."
    explanation: Review confirms motor neuron loss as the pathological basis of SMA.
  downstream:
  - target: Hypotonia
    description: Early denervation reduces baseline muscle tone.
  - target: Progressive Muscle Weakness
    description: Ongoing denervation and muscle atrophy cause steadily worsening weakness.
  - target: Areflexia
    description: Loss of lower motor neurons reduces deep tendon reflex arcs.
  - target: Tongue Fasciculations
    description: Chronically denervated motor units generate spontaneous discharges visible as tongue fasciculations.
  - target: Respiratory Motor Unit Failure
    description: Involvement of phrenic and intercostal motor neurons compromises ventilation.
  - target: Axial Muscle Imbalance
    description: Persistent truncal denervation produces progressive postural instability.
  - target: Skeletal Muscle Atrophy
  - target: Proximal Muscle Weakness
  - target: Dysphagia
  - target: Bulbar Palsy
  - target: Constipation
    description: Denervation and bulbar/autonomic motor dysfunction can impair gastrointestinal motility.
  - target: Gastroesophageal Reflux
    description: Bulbar and respiratory motor-unit weakness predisposes to reflux and related feeding dysfunction.
  - target: Inability to Walk
  - target: Difficulty Climbing Stairs
  - target: Fatigue
  - target: Flexion Contracture
  - target: Gait Disturbance
  - target: Poor Suck
  - target: Distal Muscle Weakness
  - target: Axial Muscle Weakness
  - target: Quadriceps Muscle Weakness
  - target: Weakness of Facial Musculature
  - target: Difficulty Running
  - target: Triceps Weakness
- name: Respiratory Motor Unit Failure
  description: >
    Denervation of diaphragm and intercostal muscles reduces tidal volume, cough
    strength, and airway clearance, predisposing to respiratory decompensation.
  downstream:
  - target: Respiratory Failure
    description: Progressive ventilatory muscle weakness culminates in chronic or acute respiratory failure.
  - target: Recurrent Aspiration Pneumonia
  - target: Respiratory Insufficiency Due to Muscle Weakness
  - target: Intercostal Muscle Weakness
  - target: Neonatal Respiratory Distress
- name: Axial Muscle Imbalance
  description: >
    Asymmetric weakness of paraspinal and truncal muscles during growth leads to
    progressive spinal curvature.
  downstream:
  - target: Scoliosis
    description: Chronic axial weakness and imbalance drives neuromuscular scoliosis.
  - target: Hip Dislocation
- name: SMN-Dependent Neurodevelopmental Disruption
  description: >
    SMN deficiency during critical developmental windows disrupts neural progenitor
    dynamics, synapse formation, circuit assembly, and neuron-glia interactions
    beyond the motor system. These disturbances affect cortical and cerebellar
    networks, conferring vulnerability to higher-order brain functions including
    cognition, expressive language, executive function, social communication, and
    behavioral regulation. Even with early disease-modifying therapy, developmental
    constraints and limited plasticity of specific neural circuits can leave
    persistent neurodevelopmental vulnerabilities.
  cell_types:
  - preferred_term: Neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  - preferred_term: Pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  biological_processes:
  - preferred_term: Neurogenesis
    term:
      id: GO:0022008
      label: neurogenesis
    modifier: DECREASED
  - preferred_term: Synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: DECREASED
  - preferred_term: Axonogenesis
    term:
      id: GO:0007409
      label: axonogenesis
    modifier: DECREASED
  evidence:
  - reference: PMID:42189425
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from experimental models demonstrates that early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows. These disturbances affect not only spinal motor circuits but also broader cortical and cerebellar networks, thereby conferring vulnerability to higher-order brain functions."
    explanation: Review synthesizes model evidence that SMN deficiency disrupts neurodevelopment across multiple CNS circuits beyond motor neurons.
  - reference: PMID:42189425
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous. Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
    explanation: Human clinical observations in the DMT era support persistent, domain-specific neurodevelopmental vulnerabilities despite early treatment.
  downstream:
  - target: Neurodevelopmental Vulnerability
    description: Early disrupted neurodevelopment confers persistent cognitive, language, executive, behavioral, and social communication vulnerability.
  - target: Expressive Language Delay
    description: Language-relevant neural circuits in cortex are vulnerable to developmental SMN deficiency.
  - target: Executive Dysfunction
    description: Disrupted synaptic development and circuit assembly affect executive-control networks.
  - target: Social Communication Vulnerability
    description: Neurodevelopmental disruption contributes to social communication vulnerabilities in treated SMA.
  - target: Global Developmental Delay
  - target: Autism Spectrum Manifestations
- name: Neuron-Glia Interactions
  description: >
    SMN deficiency impairs communication between neurons and glial cells (astrocytes,
    oligodendrocytes, microglia), disrupting myelin formation, metabolic support,
    and immune homeostasis during critical developmental periods.
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
    modifier: DECREASED
  - preferred_term: Neuroinflammation
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:42189425
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from experimental models demonstrates that early SMN deficiency disrupts neural progenitor dynamics, synapse formation, circuit assembly, and neuron-glia interactions during critical developmental windows."
    explanation: Review identifies neuron-glia interactions as a key mechanism disrupted by SMN deficiency during development.
  downstream:
  - target: Neurodevelopmental Vulnerability
    description: Disrupted neuron-glia support during developmental windows contributes to persistent neurodevelopmental vulnerability.
  - target: Executive Dysfunction
    description: Altered myelination and inflammatory signaling can affect circuits supporting executive control.
phenotypes:
- name: Hypotonia
  category: Neurological
  frequency: OCCASIONAL
  diagnostic: true
  notes: Floppy infant presentation in severe forms; Orphanet rates occasional across the full proximal SMA spectrum (very frequent in Type 1, mild/absent in Types 3-4).
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:18572081
    reference_title: "Spinal muscular atrophy."
    supports: SUPPORT
    snippet: "Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."
    explanation: Lancet review confirms generalized weakness as a characteristic of SMA, presenting as hypotonia in infants.
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Occasional (29-5%)"
    explanation: Orphanet lists hypotonia as an occasional phenotype of proximal SMA.
- name: Progressive Muscle Weakness
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Symmetric, proximal greater than distal
  phenotype_term:
    preferred_term: Progressive Muscle Weakness
    term:
      id: HP:0003323
      label: Progressive muscle weakness
  evidence:
  - reference: PMID:16364894
    reference_title: "Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease."
    supports: SUPPORT
    snippet: "The disease results in motor neuron loss and skeletal muscle atrophy."
    explanation: Review confirms skeletal muscle atrophy (weakness) as a direct result of motor neuron loss in SMA.
- name: Areflexia
  category: Neurological
  frequency: FREQUENT
  notes: Absent deep tendon reflexes
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:18572081
    reference_title: "Spinal muscular atrophy."
    supports: SUPPORT
    snippet: "Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."
    explanation: Motor neuron degeneration leads to loss of deep tendon reflexes (areflexia).
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001284 | Areflexia | Frequent (79-30%)"
    explanation: Orphanet lists areflexia as a frequent phenotype of proximal SMA.
- name: Tongue Fasciculations
  category: Neurological
  frequency: FREQUENT
  notes: Tongue fasciculations are particularly characteristic of SMA and a key clinical diagnostic sign.
  phenotype_term:
    preferred_term: Tongue fasciculations
    term:
      id: HP:0001308
      label: Tongue fasciculations
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001308 | Tongue fasciculations | Frequent (79-30%)"
    explanation: Orphanet lists tongue fasciculations as a frequent phenotype of proximal SMA.
- name: Respiratory Failure
  category: Respiratory
  frequency: OCCASIONAL
  notes: Leading cause of death in SMA types 1 and 2; Orphanet rates occasional across the full proximal SMA spectrum.
  phenotype_term:
    preferred_term: Respiratory Failure
    term:
      id: HP:0002878
      label: Respiratory failure
  evidence:
  - reference: PMID:29091570
    reference_title: "Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy."
    supports: SUPPORT
    snippet: "the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005)."
    explanation: ENDEAR trial uses permanent assisted ventilation as a primary endpoint, confirming respiratory failure as a key clinical outcome in infantile SMA.
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002878 | Respiratory failure | Occasional (29-5%)"
    explanation: Orphanet lists respiratory failure as an occasional phenotype of proximal SMA.
- name: Scoliosis
  category: Musculoskeletal
  frequency: OCCASIONAL
  notes: Progressive spinal curvature due to paraspinal muscle weakness; Orphanet rates occasional across the full proximal SMA spectrum.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:16364894
    reference_title: "Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease."
    supports: SUPPORT
    snippet: "The disease results in motor neuron loss and skeletal muscle atrophy."
    explanation: Progressive muscle weakness including paraspinal muscles leads to scoliosis in SMA patients.
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002650 | Scoliosis | Occasional (29-5%)"
    explanation: Orphanet lists scoliosis as an occasional phenotype of proximal SMA.
- name: Skeletal Muscle Atrophy
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  notes: Orphanet classifies skeletal muscle atrophy as very frequent (99-80%) in proximal SMA.
  phenotype_term:
    preferred_term: Skeletal muscle atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003202 | Skeletal muscle atrophy | Very frequent (99-80%)"
    explanation: Orphanet lists skeletal muscle atrophy as very frequent in proximal SMA.
  - reference: PMID:16364894
    reference_title: "Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease results in motor neuron loss and skeletal muscle atrophy."
    explanation: Review confirms skeletal muscle atrophy as a core feature of SMA.
- name: Proximal Muscle Weakness
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  notes: Orphanet classifies proximal muscle weakness as very frequent (99-80%) in proximal SMA.
  phenotype_term:
    preferred_term: Proximal muscle weakness
    term:
      id: HP:0003701
      label: Proximal muscle weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003701 | Proximal muscle weakness | Very frequent (99-80%)"
    explanation: Orphanet lists proximal muscle weakness as very frequent in proximal SMA.
- name: Dysphagia
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Orphanet classifies dysphagia as frequent (79-30%); swallowing difficulties are common especially in severe types.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002015 | Dysphagia | Frequent (79-30%)"
    explanation: Orphanet lists dysphagia as a frequent phenotype of proximal SMA.
- name: Bulbar Palsy
  category: Neurological
  frequency: FREQUENT
  notes: Orphanet classifies bulbar palsy as frequent (79-30%); bulbar motor neuron involvement causes feeding and speech difficulties.
  phenotype_term:
    preferred_term: Bulbar palsy
    term:
      id: HP:0001283
      label: Bulbar palsy
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001283 | Bulbar palsy | Frequent (79-30%)"
    explanation: Orphanet lists bulbar palsy as a frequent phenotype of proximal SMA.
- name: Recurrent Aspiration Pneumonia
  category: Respiratory
  frequency: FREQUENT
  notes: Orphanet classifies recurrent aspiration pneumonia as frequent (79-30%); dysphagia and weak cough predispose to aspiration.
  phenotype_term:
    preferred_term: Recurrent aspiration pneumonia
    term:
      id: HP:0002100
      label: Recurrent aspiration pneumonia
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002100 | Recurrent aspiration pneumonia | Frequent (79-30%)"
    explanation: Orphanet lists recurrent aspiration pneumonia as a frequent phenotype of proximal SMA.
- name: Respiratory Insufficiency Due to Muscle Weakness
  category: Respiratory
  frequency: FREQUENT
  notes: Orphanet classifies respiratory insufficiency due to muscle weakness as frequent (79-30%).
  phenotype_term:
    preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002747 | Respiratory insufficiency due to muscle weakness | Frequent (79-30%)"
    explanation: Orphanet lists respiratory insufficiency due to muscle weakness as a frequent phenotype of proximal SMA.
- name: Inability to Walk
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies inability to walk as frequent (79-30%); SMA types 1 and 2 patients are typically non-ambulatory.
  phenotype_term:
    preferred_term: Inability to walk
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002540 | Inability to walk | Frequent (79-30%)"
    explanation: Orphanet lists inability to walk as a frequent phenotype of proximal SMA.
- name: Intercostal Muscle Weakness
  category: Respiratory
  frequency: FREQUENT
  notes: Orphanet classifies intercostal muscle weakness as frequent (79-30%); contributes to paradoxical breathing pattern.
  phenotype_term:
    preferred_term: Intercostal muscle weakness
    term:
      id: HP:0004878
      label: Intercostal muscle weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004878 | Intercostal muscle weakness | Frequent (79-30%)"
    explanation: Orphanet lists intercostal muscle weakness as a frequent phenotype of proximal SMA.
- name: Difficulty Climbing Stairs
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies difficulty climbing stairs as frequent (79-30%); hallmark of proximal weakness in ambulatory SMA patients.
  phenotype_term:
    preferred_term: Difficulty climbing stairs
    term:
      id: HP:0003551
      label: Difficulty climbing stairs
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003551 | Difficulty climbing stairs | Frequent (79-30%)"
    explanation: Orphanet lists difficulty climbing stairs as a frequent phenotype of proximal SMA.
- name: Fatigue
  category: General
  frequency: FREQUENT
  notes: Orphanet classifies fatigue as frequent (79-30%).
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012378 | Fatigue | Frequent (79-30%)"
    explanation: Orphanet lists fatigue as a frequent phenotype of proximal SMA.
- name: Flexion Contracture
  category: Musculoskeletal
  frequency: OCCASIONAL
  notes: Orphanet classifies flexion contracture as occasional (29-5%); develops secondary to chronic immobility and muscle weakness.
  phenotype_term:
    preferred_term: Flexion contracture
    term:
      id: HP:0001371
      label: Flexion contracture
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001371 | Flexion contracture | Occasional (29-5%)"
    explanation: Orphanet lists flexion contracture as an occasional phenotype of proximal SMA.
- name: Constipation
  category: Gastrointestinal
  frequency: OCCASIONAL
  notes: Orphanet classifies constipation as occasional (29-5%); due to reduced abdominal muscle tone and immobility.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002019 | Constipation | Occasional (29-5%)"
    explanation: Orphanet lists constipation as an occasional phenotype of proximal SMA.
- name: Gastroesophageal Reflux
  category: Gastrointestinal
  frequency: OCCASIONAL
  notes: Orphanet classifies gastroesophageal reflux as occasional (29-5%).
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002020 | Gastroesophageal reflux | Occasional (29-5%)"
    explanation: Orphanet lists gastroesophageal reflux as an occasional phenotype of proximal SMA.
- name: Hip Dislocation
  category: Musculoskeletal
  frequency: OCCASIONAL
  notes: Orphanet classifies hip dislocation as occasional (29-5%); secondary to muscle weakness and contractures.
  phenotype_term:
    preferred_term: Hip dislocation
    term:
      id: HP:0002827
      label: Hip dislocation
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002827 | Hip dislocation | Occasional (29-5%)"
    explanation: Orphanet lists hip dislocation as an occasional phenotype of proximal SMA.
- name: Gait Disturbance
  category: Neurological
  frequency: FREQUENT
  notes: Orphanet classifies gait disturbance as frequent (79-30%); characteristic waddling gait in ambulatory SMA patients.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
    explanation: Orphanet lists gait disturbance as a frequent phenotype of proximal SMA.
- name: Poor Suck
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Orphanet classifies poor suck as frequent (79-30%); particularly relevant in SMA types 1 and 2.
  phenotype_term:
    preferred_term: Poor suck
    term:
      id: HP:0002033
      label: Poor suck
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002033 | Poor suck | Frequent (79-30%)"
    explanation: Orphanet lists poor suck as a frequent phenotype of proximal SMA.
- name: Distal Muscle Weakness
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies distal muscle weakness as frequent (79-30%); proximal weakness predominates but distal involvement occurs.
  phenotype_term:
    preferred_term: Distal muscle weakness
    term:
      id: HP:0002460
      label: Distal muscle weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002460 | Distal muscle weakness | Frequent (79-30%)"
    explanation: Orphanet lists distal muscle weakness as a frequent phenotype of proximal SMA.
- name: Neonatal Respiratory Distress
  category: Respiratory
  frequency: FREQUENT
  notes: Orphanet classifies neonatal respiratory distress as frequent (79-30%); particularly in SMA type 1 infants.
  phenotype_term:
    preferred_term: Neonatal respiratory distress
    term:
      id: HP:0002643
      label: Neonatal respiratory distress
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002643 | Neonatal respiratory distress | Frequent (79-30%)"
    explanation: Orphanet lists neonatal respiratory distress as a frequent phenotype of proximal SMA.
- name: Axial Muscle Weakness
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies axial muscle weakness as frequent (79-30%); contributes to head lag and truncal instability.
  phenotype_term:
    preferred_term: Axial muscle weakness
    term:
      id: HP:0003327
      label: Axial muscle weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003327 | Axial muscle weakness | Frequent (79-30%)"
    explanation: Orphanet lists axial muscle weakness as a frequent phenotype of proximal SMA.
- name: Quadriceps Muscle Weakness
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies quadriceps muscle weakness as frequent (79-30%).
  phenotype_term:
    preferred_term: Quadriceps muscle weakness
    term:
      id: HP:0003731
      label: Quadriceps muscle weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003731 | Quadriceps muscle weakness | Frequent (79-30%)"
    explanation: Orphanet lists quadriceps muscle weakness as a frequent phenotype of proximal SMA.
- name: Weakness of Facial Musculature
  category: Neurological
  frequency: FREQUENT
  notes: Orphanet classifies weakness of facial musculature as frequent (79-30%).
  phenotype_term:
    preferred_term: Weakness of facial musculature
    term:
      id: HP:0030319
      label: Weakness of facial musculature
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0030319 | Weakness of facial musculature | Frequent (79-30%)"
    explanation: Orphanet lists weakness of facial musculature as a frequent phenotype of proximal SMA.
- name: Difficulty Running
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies difficulty running as frequent (79-30%); early sign in ambulatory SMA patients.
  phenotype_term:
    preferred_term: Difficulty running
    term:
      id: HP:0009046
      label: Difficulty running
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009046 | Difficulty running | Frequent (79-30%)"
    explanation: Orphanet lists difficulty running as a frequent phenotype of proximal SMA.
- name: Triceps Weakness
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Orphanet classifies triceps weakness as frequent (79-30%).
  phenotype_term:
    preferred_term: Triceps weakness
    term:
      id: HP:0031108
      label: Triceps weakness
  evidence:
  - reference: ORPHA:70
    reference_title: "Proximal spinal muscular atrophy (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031108 | Triceps weakness | Frequent (79-30%)"
    explanation: Orphanet lists triceps weakness as a frequent phenotype of proximal SMA.
- name: Global Developmental Delay
  category: Neurological
  frequency: OCCASIONAL
  notes: >-
    Subtle neurodevelopmental vulnerabilities persist even with early DMT treatment.
    Pre-DMT studies reported preserved cognition but were shaped by survival bias
    and motor-dependent assessment tools. Contemporary studies reveal heterogeneous
    outcomes with recognition of higher-order brain function involvement.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:42189425
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pre-DMT clinical studies reporting preserved cognition were shaped by survival bias, motor-dependent assessment tools, and limited evaluation of non-motor domains. In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous."
    explanation: >
      Review demonstrates that neurodevelopmental vulnerability is a core feature
      of SMA even in the DMT era, affecting cognition, language, and behavior
      beyond motor function.
- name: Neurodevelopmental Vulnerability
  category: Neurological
  frequency: OCCASIONAL
  diagnostic: false
  notes: In the disease-modifying therapy (DMT) era, presymptomatic treatment has improved developmental outcomes; however, subtle cognitive, language, behavioral, executive function, and social communication vulnerabilities remain heterogeneous even among optimally treated individuals. These vulnerabilities reflect biological constraints imposed by developmental timing and limited plasticity of specific neural circuits affected by early SMN deficiency.
  phenotype_term:
    preferred_term: Neurodevelopmental abnormality
    term:
      id: HP:0012759
      label: Neurodevelopmental abnormality
  evidence:
  - reference: PMID:42189425
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the DMT era, presymptomatic treatment has markedly improved developmental outcomes; nevertheless, cognitive, language, and behavioral phenotypes remain heterogeneous. Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
    explanation: Review documents persistent, domain-specific neurodevelopmental vulnerabilities in optimally treated SMA without implying broad global developmental delay.
  - reference: PMID:42189425
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings align with biological constraints imposed by developmental timing and limited plasticity of specific neural circuits."
    explanation: Review links persistent vulnerabilities to developmental timing and limited plasticity after early SMN deficiency.
- name: Expressive Language Delay
  category: Neurological
  diagnostic: false
  notes: Subtle expressive language vulnerabilities are increasingly recognized in DMT-treated individuals, reflecting developmental constraints of language-relevant neural circuits vulnerable to SMN deficiency.
  phenotype_term:
    preferred_term: Expressive language delay
    term:
      id: HP:0002474
      label: Expressive language delay
  evidence:
  - reference: PMID:42189425
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
    explanation: >
      Contemporary evidence shows expressive language delay as a recognized phenotype
      of SMA in the treatment era, reflecting the broader neurodevelopmental
      impact of SMN deficiency.
- name: Executive Dysfunction
  category: Neurological
  frequency: OCCASIONAL
  notes: >-
    Deficits in executive function represent a subtle neurodevelopmental
    vulnerability persisting despite improved motor outcomes with DMT.
  evidence:
  - reference: PMID:42189425
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
    explanation: >
      Review identifies executive dysfunction as a neurodevelopmental outcome
      of early SMN deficiency affecting higher-order brain functions.
  diagnostic: false
  phenotype_term:
    preferred_term: Impaired executive functioning
    term:
      id: HP:0033051
      label: Impaired executive functioning
- name: Autism Spectrum Manifestations
  category: Behavioral
  frequency: OCCASIONAL
  notes: >-
    Social communication and behavioral phenotypes reflect the broader
    neurodevelopmental impact of SMN deficiency beyond motor neuron
    pathology, particularly affecting social and communicative domains.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:42189425
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals. These findings align with biological constraints imposed by developmental timing and limited plasticity of specific neural circuits."
    explanation: >
      SMN-dependent disruption of cortical and cerebellar networks confers
      vulnerability to social and communicative development even with early
      intervention.
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
- name: Social Communication Vulnerability
  category: Neurological
  diagnostic: false
  notes: Social communication vulnerabilities are increasingly recognized in DMT-treated individuals as part of the broader non-motor neurodevelopmental phenotype.
  phenotype_term:
    preferred_term: Social communication vulnerability
    term:
      id: HP:0012433
      label: Abnormal social behavior
  evidence:
  - reference: PMID:42189425
    reference_title: "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subtle vulnerabilities-particularly in expressive language, executive function, and social communication-are increasingly recognized, even among optimally treated individuals."
    explanation: Review explicitly identifies social communication as a neurodevelopmental vulnerability in DMT-treated SMA.
biochemical:
- name: Creatine Kinase
  presence: Normal or mildly elevated
  context: Unlike muscular dystrophies, CK is typically normal or only mildly elevated
genetic:
- name: SMN1
  association: Causative
  notes: Autosomal recessive, homozygous deletion in 95% of cases, compound heterozygotes in remainder
  evidence:
  - reference: PMID:18572081
    reference_title: "Spinal muscular atrophy."
    supports: SUPPORT
    snippet: "It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation."
    explanation: Lancet review confirms SMN1 gene disruption is the causative mechanism of SMA.
- name: SMN2
  association: Modifier
  notes: Copy number inversely correlates with severity; more copies = milder phenotype
treatments:
- name: Nusinersen (Spinraza)
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  aso_details:
    aso_mechanism: SPLICE_MODULATION_EXON_INCLUSION
    target_gene:
      preferred_term: SMN2
      term:
        id: hgnc:11118
        label: SMN2
    target_transcript: SMN2 pre-mRNA (ISS-N1)
    target_exon: exon 7
    aso_chemistry: TWO_PRIME_O_METHOXYETHYL
    conjugation: UNCONJUGATED
  description: Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration.
  evidence:
  - reference: PMID:29091570
    reference_title: "Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy."
    supports: SUPPORT
    snippet: "Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group."
    explanation: ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA.
  - reference: PMID:29091570
    reference_title: "Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy."
    supports: SUPPORT
    snippet: "Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein."
    explanation: NEJM paper confirms mechanism of action of nusinersen.
- name: Onasemnogene abeparvovec (Zolgensma)
  description: AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion.
  evidence:
  - reference: PMID:35715567
    reference_title: "Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial."
    supports: SUPPORT
    snippet: "Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention."
    explanation: SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants.
- name: Risdiplam (Evrysdi)
  description: Oral small molecule SMN2 splicing modifier, daily oral administration.
  evidence:
  - reference: PMID:34320287
    reference_title: "Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls."
    supports: SUPPORT
    snippet: "In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts."
    explanation: FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA.
- name: Supportive Care
  description: Respiratory support, nutritional management, physical therapy, orthopedic interventions.
- name: Multidisciplinary Care and Rehabilitation Management (2018 SMA Care Group, Part 1)
  description: >-
    The 2018 SMA Care Group consensus update provides evidence-based recommendations
    for diagnosis, rehabilitation, orthopedic and spinal management, and nutritional,
    swallowing and gastrointestinal care across SMA subtypes. It updates the 2007
    International Conference on the Standard of Care for SMA, the foundational
    global consensus, with Part 2 separately addressing pulmonary and acute management.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:29290580
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 2007, an International Conference on the Standard of Care for SMA published a consensus statement on SMA standard of care that has been widely used throughout the world. Here we report a two-part update of the topics covered in the previous recommendations."
    explanation: >-
      Establishes this document as the formal 2018 update to the 2007 globally
      adopted SMA standard-of-care consensus.
  - reference: PMID:29290580
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an update on diagnosis, rehabilitation, orthopedic and spinal management; and nutritional, swallowing and gastrointestinal management"
    explanation: >-
      Defines the four care domains covered in Part 1: rehabilitation, orthopedic/spinal,
      and nutritional/gastrointestinal management across SMA subtypes.
  - reference: PMID:29290580
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pulmonary management, acute care, other organ involvement, ethical issues, medications, and the impact of new treatments for SMA are discussed in part 2."
    explanation: >-
      Documents the full multisystem scope of the two-part consensus update;
      pulmonary and acute care are addressed in the companion Part 2 document.
datasets:
- accession: geo:GSE56284
  title: Transcriptome profiling of severe spinal muscular atrophy mouse embryonic stem cell-derived motor neurons
  description: RNA-seq profiling of mouse embryonic stem cell-derived motor neurons from SMA model and control lines.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: motor neuron
    cell_type_term:
      preferred_term: motor neuron
      term:
        id: CL:0000100
        label: motor neuron
  sample_count: 6
  conditions:
  - SMA mouse model
  - control
  notes: D7 Hb9:GFP mESC-derived motor neurons from SMA and control lines.
discussions:
- discussion_id: gap_sma_microrna_primary_vs_secondary
  prompt: >-
    Is early microRNA accumulation in SMA (specifically miR-128-3p dysregulation)
    a primary pathogenic initiating event upstream of SMN-driven motor neuron
    degeneration, or a secondary consequence of SMN deficiency? The temporal
    relationship between SMN loss and microRNA dysregulation remains mechanistically
    unclear. Additionally, does the miR-128-3p→Hipk2 regulatory axis contribute
    directly to motor neuron injury, or does it represent a downstream marker of
    broader RNA metabolism dysfunction?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#SMN Protein Deficiency
  - pathophysiology#Motor Neuron Degeneration
  rationale: >-
    The SMN1 deficiency in SMA leads to widespread disruption in RNA metabolism,
    including dysregulation of microRNAs. PMID:42260294 demonstrates that early
    microRNA accumulation in SMA mouse spinal cords can contribute to molecular
    dysfunctions and "may represent an initiating event in pathogenesis." However,
    whether microRNA dysregulation is an upstream driver of pathology or a
    secondary consequence of SMN loss remains unresolved. The specific miR-128-3p
    inhibitor was shown to interfere with flunarizine-induced neurite outgrowth
    in vitro, and Hipk2 was identified as a novel miR-128-3p target, suggesting
    a potentially druggable axis. Determining the causal vs. reactive nature of
    this dysregulation is critical for mechanism-based therapeutic design.
  evidence:
  - reference: PMID:42260294
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "early microRNA accumulation in spinal cords of SMA models can contribute to molecular dysfunctions and may represent an initiating event in pathogenesis"
    explanation: Mouse SMA model data demonstrating early miR-128-3p dysregulation and its contribution to molecular dysfunction.
  proposed_experiments:
  - experiment_id: exp_sma_temporal_microrna_smn
    name: Temporal kinetics of SMN loss versus microRNA dysregulation in SMA models
    description: >-
      Use inducible SMN degradation (degron) systems in mouse SMA models or
      patient-derived fibroblasts to establish the temporal relationship between
      SMN protein depletion and miR-128-3p accumulation. Measure SMN levels,
      miR-128-3p expression, Hipk2 mRNA/protein, and early neurite outgrowth
      markers at precise time intervals to determine whether miR-128-3p elevation
      precedes, follows, or is concurrent with SMN loss. If microRNA changes
      precede motor neuron degeneration, this would support a primary pathogenic
      role; if reactive, therapeutic targeting must address upstream SMN
      deficiency.
    experiment_type:
      preferred_term: temporal kinetics study with molecular markers
    model_systems:
    - name: Inducible SMN degradation SMA mouse model
      description: >-
        Mouse expressing an SMN-degron fusion allowing rapid, controlled SMN
        depletion via doxycycline or other degron system, enabling precise
        temporal measurement of downstream molecular events (miR-128-3p,
        Hipk2, neurodevelopmental markers).
      experimental_model_type: OTHER
  - experiment_id: exp_sma_microrna_inhibition_rescue
    name: miR-128-3p inhibition rescue of motor neuron degeneration in vivo
    description: >-
      Test whether early inhibition of miR-128-3p (e.g., with antagomiR or ASO
      blocking miR-128-3p) in presymptomatic or early symptomatic SMA mouse models
      rescues motor neuron survival and delays disease progression independently
      of SMN restoration. Measure motor neuron counts, motor function (rotarod,
      grip strength), lifespan, and spinal miRNA levels. If miR-128-3p inhibition
      provides significant rescue without restoring SMN, this would indicate a
      primary pathogenic role; limited/no rescue would suggest secondary status.
    experiment_type:
      preferred_term: antisense oligonucleotide or antagomiR in vivo efficacy
    model_systems:
    - name: SMA mouse model with locked miR-128-3p inhibitor
      description: >-
        Severe SMA mouse model (Smn1-/-; Smn2 transgene) treated with
        miR-128-3p antagomiR or locked nucleic acid (LNA) inhibitor delivered
        neonatally or in early postnatal period to assess whether miRNA inhibition
        alone can modify motor neuron and behavioral phenotypes.
      experimental_model_type: OTHER
  - experiment_id: exp_sma_hipk2_axis_causality
    name: Hipk2-dependent vs. independent effects of miR-128-3p in motor neurons
    description: >-
      Generate motor neurons (iPSC-derived or transgenic mouse neurons) with
      miR-128-3p overexpression, and compare phenotypes in isogenic Hipk2-wildtype
      vs. Hipk2-knockout backgrounds. If Hipk2 loss fully rescues miR-128-3p
      overexpression phenotypes, this indicates Hipk2 is the canonical target
      mediating miRNA toxicity. Evaluate neurite outgrowth, synaptic markers,
      and cell viability. Discordant rescue would suggest off-target effects of
      miR-128-3p.
    experiment_type:
      preferred_term: isogenic genetic background comparison in iPSC-derived neurons
    model_systems:
    - name: Human iPSC-derived motor neurons with miR-128-3p and Hipk2 perturbations
      description: >-
        Motor neurons differentiated from patient-derived SMA iPSCs or
        gene-edited controls, with CRISPR/Cas9-mediated knockout or overexpression
        of miR-128-3p and Hipk2 to dissect the regulatory axis in a disease-relevant
        human cellular context.
      experimental_model_type: IPSC_DERIVED_MODEL
references:
- reference: PMID:29290580
  title: "Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care."
- reference: PMID:42260294
  title: "Flunarizine changes microRNA expression in cell cultures and in a mouse model of spinal muscular atrophy"
  findings: []
- reference: PMID:20301526
  title: "Spinal Muscular Atrophy"
  tags:
  - GeneReviews
- reference: DOI:10.1007/s00415-024-12724-3
  title: Cytoskeleton dysfunction of motor neuron in spinal muscular atrophy
  findings: []
- reference: DOI:10.1007/s00431-024-05886-9
  title: 'Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study'
  findings: []
- reference: DOI:10.1016/j.ejpn.2024.06.001
  title: '2024 update: European consensus statement on gene therapy for spinal muscular atrophy'
  findings: []
- reference: DOI:10.1042/bst20231116
  title: 'The SMN-ribosome interplay: a new opportunity for Spinal Muscular Atrophy therapies'
  findings: []
- reference: DOI:10.1093/braincomms/fcae239
  title: Role of senataxin in R-loop-mediated neurodegeneration
  findings: []
- reference: DOI:10.1172/jci.insight.180992
  title: Characterization of SMA type II skeletal muscle from treated patients shows OXPHOS deficiency and denervation
  findings: []
- reference: DOI:10.1186/s12915-024-01888-z
  title: Dysregulation of innate immune signaling in animal models of spinal muscular atrophy
  findings: []
- reference: DOI:10.3233/jnd-230122
  title: 'Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry'
  findings: []
- reference: DOI:10.3389/fncel.2023.1307636
  title: 'Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches'
  findings: []
- reference: DOI:10.3390/genes15080999
  title: 'Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges'
  findings: []
- reference: DOI:10.3390/ijms25137311
  title: 'Beyond Motor Neurons in Spinal Muscular Atrophy: A Focus on Neuromuscular Junction'
  findings: []
- reference: DOI:10.3390/ijms252011210
  title: In Search of Spinal Muscular Atrophy Disease Modifiers
  findings: []
📚

References & Deep Research

References

15
PMID:29290580
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.
No top-level findings curated for this source.
PMID:42260294
Flunarizine changes microRNA expression in cell cultures and in a mouse model of spinal muscular atrophy
No top-level findings curated for this source.
PMID:20301526
Spinal Muscular Atrophy
No top-level findings curated for this source.
DOI:10.1007/s00415-024-12724-3
Cytoskeleton dysfunction of motor neuron in spinal muscular atrophy
No top-level findings curated for this source.
DOI:10.1007/s00431-024-05886-9
Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study
No top-level findings curated for this source.
DOI:10.1016/j.ejpn.2024.06.001
2024 update: European consensus statement on gene therapy for spinal muscular atrophy
No top-level findings curated for this source.
DOI:10.1042/bst20231116
The SMN-ribosome interplay: a new opportunity for Spinal Muscular Atrophy therapies
No top-level findings curated for this source.
DOI:10.1093/braincomms/fcae239
Role of senataxin in R-loop-mediated neurodegeneration
No top-level findings curated for this source.
DOI:10.1172/jci.insight.180992
Characterization of SMA type II skeletal muscle from treated patients shows OXPHOS deficiency and denervation
No top-level findings curated for this source.
DOI:10.1186/s12915-024-01888-z
Dysregulation of innate immune signaling in animal models of spinal muscular atrophy
No top-level findings curated for this source.
DOI:10.3233/jnd-230122
Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry
No top-level findings curated for this source.
DOI:10.3389/fncel.2023.1307636
Autophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches
No top-level findings curated for this source.
DOI:10.3390/genes15080999
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
No top-level findings curated for this source.
DOI:10.3390/ijms25137311
Beyond Motor Neurons in Spinal Muscular Atrophy: A Focus on Neuromuscular Junction
No top-level findings curated for this source.
DOI:10.3390/ijms252011210
In Search of Spinal Muscular Atrophy Disease Modifiers
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Spinal Muscular Atrophy
  • Category: Genetic
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 25

Key Pathophysiology Nodes

  • SMN Protein Deficiency
  • Motor Neuron Degeneration
  • Respiratory Motor Unit Failure
  • Axial Muscle Imbalance
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1007/s00415-024-12724-3
  • DOI:10.1007/s00431-024-05886-9
  • DOI:10.1016/j.ejpn.2024.06.001
  • DOI:10.1042/bst20231116
  • DOI:10.1093/braincomms/fcae239
  • DOI:10.1172/jci.insight.180992
  • DOI:10.1186/s12915-024-01888-z
  • DOI:10.3233/jnd-230122
  • DOI:10.3389/fncel.2023.1307636
  • DOI:10.3390/genes15080999
  • DOI:10.3390/ijms25137311
  • DOI:10.3390/ijms252011210
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 30 citations 2026-02-01T12:41:54.641457

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Spinal Muscular Atrophy (5q-SMA)
  • MONDO ID: [not provided]
  • Category: Genetic

Pathophysiology description (narrative)

Spinal muscular atrophy (SMA) is caused by homozygous disruption of SMN1, resulting in reduced survival motor neuron (SMN) protein and a spectrum of downstream defects that converge on selective degeneration of lower motor neurons, neuromuscular junction (NMJ) failure, and systemic, multi-organ abnormalities. SMN is a core component of the SMN–Gemins complex essential for spliceosomal snRNP assembly and mRNA splicing; it also associates with ribosomes and translation-related machinery, and regulates axonal/cytoskeletal dynamics and local translation. Recent work emphasizes additional mechanisms: autophagy–lysosome pathway dysregulation; accumulation of R-loops and DNA damage involving senataxin (SETX); innate immune activation; and non-neuronal contributions from muscle, glia, and mesenchymal progenitors. Importantly, SMN-restorative therapies improve outcomes but do not fully normalize downstream cellular biology, particularly in skeletal muscle and metabolism. (haque2024recentprogressin pages 1-2, glynn2025actincytoskeletondysregulation pages 21-24, shi2025cytoskeletondysfunctionof pages 1-3, torri2024beyondmotorneurons pages 1-2, grandi2024characterizationofsma pages 1-2)

Selected quotes supporting key concepts: - “The underlying cause of Spinal Muscular Atrophy (SMA) is in the reduction of survival motor neuron (SMN) protein levels due to mutations in the SMN1 gene… [SMN] has crucial roles… from ribosome biogenesis to local translation and beyond.” URL: https://doi.org/10.1042/bst20231116 (Biochemical Society Transactions, Feb 2024). (haque2024recentprogressin pages 1-2) - “In addition, low levels of senataxin (loss-of-function) in spinal muscular atrophy result in the accumulation of R-loops causing DNA damage and motor neuron degeneration.” URL: https://doi.org/10.1093/braincomms/fcae239 (Brain Communications, Jul 2024). (shi2025cytoskeletondysfunctionof pages 1-3) - “Despite… SMN-dependent disease-modifying therapies… we observed a consistent loss of oxidative phosphorylation (OXPHOS) machinery of the mitochondria… and a correlation between… denervation and increased fibrosis” in treated SMA type II muscle. URL: https://doi.org/10.1172/jci.insight.180992 (JCI Insight, Sep 2024). (grandi2024characterizationofsma pages 1-2)

1. Core Pathophysiology

  • Primary mechanisms
  • SMN1 loss → reduced SMN protein → defective snRNP biogenesis and splicing, ribosome/translation control, axonal transport and cytoskeleton, and NMJ function. (haque2024recentprogressin pages 1-2, glynn2025actincytoskeletondysregulation pages 21-24, shi2025cytoskeletondysfunctionof pages 1-3, torri2024beyondmotorneurons pages 1-2)
  • Autophagy–lysosome pathway defects: reduced lysosome number/flux and TFEB/lysosomal signaling perturbation in SMA motor neurons and cells; emerging consensus implicates decreased autophagic flux. (rosignol2024understandinghowsmn pages 1-4, torres2025dissectingtherolea pages 28-32)
  • Genome instability axis: R-loop accumulation and DNA damage; SETX interacts with SMN and reduced SETX in SMA increases R-loops leading to neuronal injury. (shi2025cytoskeletondysfunctionof pages 1-3)
  • Innate immune activation: transcriptomic/proteomic studies in Drosophila SMA models show hyperactivation of IMD/Toll pathways and antimicrobial peptides, implying primary immune dysregulation from SMN loss. (chudakova2024insearchof pages 3-5)

  • Mitochondrial/OXPHOS and metabolic abnormalities: persistent skeletal muscle OXPHOS deficiency and mtDNA depletion despite therapy; denervation/fibrosis programs. (grandi2024characterizationofsma pages 1-2)

  • Dysregulated molecular pathways

  • Spliceosome/snRNP assembly; translation initiation/elongation; actin–microtubule dynamics (profilin, plastin-3, stathmin-1, MAP1B); endocytosis and vesicle trafficking at synapses; autophagy–lysosome (TFEB–mTOR); DNA damage response/R-loop resolution (SETX); innate immunity (IMD/Toll-like signaling). (haque2024recentprogressin pages 1-2, glynn2025actincytoskeletondysregulation pages 21-24, shi2025cytoskeletondysfunctionof pages 1-3, rosignol2024understandinghowsmn pages 1-4, chudakova2024insearchof pages 3-5)

  • Affected cellular processes

  • Axon growth and stability; local mRNA transport/translation; synaptic vesicle dynamics; lysosome biogenesis and autophagic flux; DNA damage repair; mitochondrial respiration and biogenesis; glia–neuron cross-talk and immune signaling. (shi2025cytoskeletondysfunctionof pages 1-3, rosignol2024understandinghowsmn pages 1-4, chudakova2024insearchof pages 3-5, grandi2024characterizationofsma pages 1-2)

2. Key Molecular Players

  • Genes/Proteins (HGNC)
  • SMN1 (HGNC:11164) and SMN2 (HGNC:11165) – causal locus and disease modifier. (haque2024recentprogressin pages 1-2, torri2024beyondmotorneurons pages 1-2)
  • SETX (HGNC:10759; senataxin) – R-loop resolution; reduced levels in SMA promote DNA damage. (shi2025cytoskeletondysfunctionof pages 1-3)
  • PFN2 (HGNC:8882), PLS3 (HGNC:9071), STMN1 (HGNC:6510) and STMN2 (HGNC:6511), MAP1B (HGNC:6830), NEFL/NEFM (neurofilaments) – cytoskeletal/axonal transport regulators; STMN2 augmentation shows therapeutic benefit in SMA models. (shi2025cytoskeletondysfunctionof pages 1-3)
  • NRXN2 (HGNC:8007), SYNCRIP (HGNC:16642) – motor neuron transcript regulation downstream of SMN. (torri2024beyondmotorneurons pages 1-2)

  • UBA1 (HGNC:12485) – ubiquitination pathway decreased with SMN loss, impacting proteostasis in muscle. (glynn2025actincytoskeletondysregulation pages 21-24)

  • Chemical entities (CHEBI; therapeutics/metabolites)

  • Nusinersen (antisense oligonucleotide; Spinraza) – SMN2 splicing modifier. (torri2024beyondmotorneurons pages 1-2)
  • Risdiplam (Evrysdi; CHEBI:145709) – oral SMN2 splicing modifier. (torri2024beyondmotorneurons pages 1-2)
  • Onasemnogene abeparvovec (AAV9-SMN1 gene therapy, Zolgensma) – SMN1 replacement. (torri2024beyondmotorneurons pages 1-2)

  • Prednisolone (CHEBI:8383) – concomitant steroid with OA infusion in practice. (lavie2024respiratoryoutcomesof pages 1-2)

  • Cell types (CL)

  • Spinal alpha motor neurons (CL:0000097 motor neuron) – primary vulnerable population. (torres2025dissectingtherolea pages 28-32)
  • Astrocytes (CL:0000127), microglia (CL:0000129), oligodendrocytes (CL:0000128), Schwann cells (CL:0000574) – non-cell autonomous contributors. (torri2024beyondmotorneurons pages 1-2)

  • Skeletal muscle fibers and fibro-adipogenic progenitors – muscle-intrinsic pathology and NMJ maturation support. (grandi2024characterizationofsma pages 1-2)

  • Anatomical locations (UBERON)

  • Spinal cord, ventral horn (lower motor neurons); peripheral motor axons; neuromuscular junctions; skeletal muscle (including diaphragm); liver and other peripheral organs implicated in systemic SMA. (torri2024beyondmotorneurons pages 1-2, grandi2024characterizationofsma pages 1-2)

3. Biological Processes (GO annotations; illustrative)

  • mRNA splicing via spliceosome (GO:0000398) and spliceosomal snRNP assembly (GO:0000387). (haque2024recentprogressin pages 1-2)
  • Translation (GO:0006412) and ribosome biogenesis (GO:0042254). (haque2024recentprogressin pages 1-2)
  • Axonal transport (GO:0098930) and microtubule cytoskeleton organization (GO:0000226). (shi2025cytoskeletondysfunctionof pages 1-3)
  • Autophagy (GO:0006914), lysosome organization (GO:0007040), TFEB signaling/mTOR regulation of autophagy (process-level concept). (rosignol2024understandinghowsmn pages 1-4)
  • DNA repair (GO:0006281), response to DNA damage stimulus (GO:0006974), R-loop resolution (process-level concept). (shi2025cytoskeletondysfunctionof pages 1-3)
  • Innate immune response (GO:0045087). (chudakova2024insearchof pages 3-5)
  • Mitochondrial electron transport chain/oxidative phosphorylation (GO:0022900/GO:0006119). (grandi2024characterizationofsma pages 1-2)

4. Cellular Components (GO-CC)

  • Nucleus; Cajal/Gem bodies; ribosome; cytoplasm; axon; growth cone; synapse/NMJ; stress granules; lysosome; mitochondrion. (haque2024recentprogressin pages 1-2, shi2025cytoskeletondysfunctionof pages 1-3, rosignol2024understandinghowsmn pages 1-4)

5. Disease Progression (sequence of events)

  • Genetic lesion: SMN1 homozygous deletion/mutation → reduced full-length SMN; SMN2 modulates residual SMN. (torri2024beyondmotorneurons pages 1-2, haque2024recentprogressin pages 1-2)
  • Nuclear and cytoplasmic defects: snRNP assembly/splicing defects; altered translation; impaired RNA transport/local translation in axons. (haque2024recentprogressin pages 1-2)
  • Axonal/cytoskeletal dysfunction: disrupted actin–microtubule dynamics (PFN2/PLS3/STMN1/MAP1B), impaired axonal transport and growth cones. (shi2025cytoskeletondysfunctionof pages 1-3)
  • Synaptic/NMJ abnormalities: early denervation, neurofilament accumulation, impaired vesicle dynamics, AChR clustering defects. (torres2025dissectingtherolea pages 28-32)
  • Quality control and genome stability: reduced autophagic flux/lysosomal alterations; R-loop accumulation and DNA damage with SETX deficiency. (rosignol2024understandinghowsmn pages 1-4, shi2025cytoskeletondysfunctionof pages 1-3)
  • Systemic and non-neuronal involvement: muscle-intrinsic mitochondrial OXPHOS deficit and fibrosis despite therapy; contributions from glia and mesenchymal progenitors altering NMJ maturation. (grandi2024characterizationofsma pages 1-2)
  • Clinical manifestations: hypotonia, proximal weakness, respiratory insufficiency, feeding/bulbar dysfunction, fatigability; severity stratified by SMN2 copy number and age of onset. (torri2024beyondmotorneurons pages 1-2)

6. Phenotypic Manifestations (HPO; illustrative mapping)

  • Hypotonia (HP:0001252); Proximal muscle weakness (HP:0003701); Areflexia (HP:0001284); Respiratory failure/insufficiency (HP:0002093); Feeding difficulties (HP:0011968); Fatigability (HP:0012378). (torri2024beyondmotorneurons pages 1-2)

Current applications and real-world implementations

  • Approved SMN-targeted therapies: nusinersen (ASO), risdiplam (small molecule), and onasemnogene abeparvovec (AAV9 gene replacement) have transformed outcomes; earlier treatment (including newborn screening) yields better motor function. (torri2024beyondmotorneurons pages 1-2)
  • Real-world registry outcomes (RESTORE): 168 patients treated with onasemnogene abeparvovec monotherapy (data cutoff May 23, 2022). “All patients maintained/achieved motor milestones.” Adverse events: “48.5% (n=81/167) experienced at least one treatment-emergent adverse event (AE), and 31/167 patients (18.6%) experienced at least one serious AE, of which 8/31 were considered treatment-related.” Infants identified by newborn screening had higher final CHOP INTEND scores than clinically diagnosed infants. URL: https://doi.org/10.3233/jnd-230122 (Journal of Neuromuscular Diseases, Jan 2024). (servais2024realworldoutcomesin pages 1-3)
  • Respiratory outcomes after OA: National real-world cohort of 25 children (23 SMA1, 2 SMA2), median age at OA 6.1 months; ventilation time decreased (14.3→11.1 h/day) and respiratory hospitalizations decreased by 26% in the post-treatment year; two deaths due to respiratory failure; authors conclude OA may improve respiratory outcomes but emphasize confounders and need for standardized long-term management. URL: https://doi.org/10.1007/s00431-024-05886-9 (European Journal of Pediatrics, Dec 2024). (lavie2024respiratoryoutcomesof pages 1-2)
  • 2024 European consensus update on gene therapy: updated guidance on rational use of onasemnogene abeparvovec, including considerations for older/heavier patients and integration with trial and real-world evidence; see EJPN consensus and supplementary material. URL: https://doi.org/10.1016/j.ejpn.2024.06.001 (European Journal of Paediatric Neurology, Jun 2024). (kirschner20242024updateeuropean pages 6-6)

Expert opinions and analysis

  • Reviews synthesize that SMN’s canonical (snRNP) and noncanonical (translation, cytoskeleton, trafficking) roles explain selective motor neuron vulnerability and widespread tissue involvement; combination therapies targeting cytoskeletal stability, NMJ integrity, autophagy–lysosome pathways, and genome stability (R-loops) are being explored to complement SMN restoration. (haque2024recentprogressin pages 1-2, shi2025cytoskeletondysfunctionof pages 1-3, torri2024beyondmotorneurons pages 1-2)
  • Autophagy: “decreased autophagic flux as the causative agent underlying the autophagic dysregulation observed” in SMA suggests TFEB–lysosomal axes as therapeutic targets. URL: https://doi.org/10.3389/fncel.2023.1307636 (Frontiers in Cellular Neuroscience, Jan 2024). (rosignol2024understandinghowsmn pages 1-4)
  • Innate immunity: SMN depletion can “hyperactivate” conserved immune pathways (IMD/Toll), indicating immune dysregulation is a primary consequence of low SMN, not merely secondary to degeneration. URL: https://doi.org/10.1186/s12915-024-01888-z (BMC Biology, Apr 2024). (chudakova2024insearchof pages 3-5)

Relevant statistics and data from recent studies

  • RESTORE registry OA monotherapy (n=168): 47.6% two SMN2 copies; 41.7% three copies; 58.3% identified by newborn screening. All achieved/maintained milestones; TEAEs in 48.5%, SAEs in 18.6% with 8 treatment-related. URL: https://doi.org/10.3233/jnd-230122 (published 2024-01-18 online). (servais2024realworldoutcomesin pages 1-3)
  • Respiratory real-world cohort after OA (n=25): 26% reduction in respiratory hospitalizations per life-year; ventilation time decreased by 3.2 h/day among survivors; 2/25 deaths from respiratory failure within study year. URL: https://doi.org/10.1007/s00431-024-05886-9 (published 2024-12). (lavie2024respiratoryoutcomesof pages 1-2)
  • Treated SMA type II muscle: consistent OXPHOS loss and mtDNA copy number decrease despite restored SMN transcripts/protein in many patients. URL: https://doi.org/10.1172/jci.insight.180992 (published 2024-09-12). (grandi2024characterizationofsma pages 1-2)

Evidence items (with direct quotes, PMIDs/DOIs/URLs where available)

1) SMN roles across translation and ribosomes: “Given the crucial roles of the SMN protein in snRNP biogenesis and its interactions with ribosomes… a decrease in SMN levels… is expected to affect translational control of gene expression.” DOI: 10.1042/bst20231116; URL: https://doi.org/10.1042/bst20231116 (Sharma et al., 2024). (haque2024recentprogressin pages 1-2) 2) R-loops and SETX in SMA: “low levels of senataxin… in spinal muscular atrophy result in the accumulation of R-loops causing DNA damage and motor neuron degeneration.” DOI: 10.1093/braincomms/fcae239; URL: https://doi.org/10.1093/braincomms/fcae239 (Kannan et al., 2024). (shi2025cytoskeletondysfunctionof pages 1-3) 3) Autophagy–lysosome: “propose decreased autophagic flux as the causative agent underlying the autophagic dysregulation observed in these patients.” DOI: 10.3389/fncel.2023.1307636; URL: https://doi.org/10.3389/fncel.2023.1307636 (Rashid & Dimitriadi, 2024). (rosignol2024understandinghowsmn pages 1-4) 4) Muscle OXPHOS deficiency despite SMN-restoration: “we observed a consistent loss of oxidative phosphorylation (OXPHOS) machinery of the mitochondria, a decrease in mitochondrial DNA copy number… [and] increased fibrosis” in treated Type II muscle. DOI: 10.1172/jci.insight.180992; URL: https://doi.org/10.1172/jci.insight.180992 (Grandi et al., 2024). (grandi2024characterizationofsma pages 1-2) 5) Real-world OA outcomes (RESTORE): “All patients maintained/achieved motor milestones. 48.5%… experienced at least one treatment-emergent adverse event… 18.6% experienced at least one serious AE…” DOI: 10.3233/jnd-230122; URL: https://doi.org/10.3233/jnd-230122 (Servais et al., 2024). (servais2024realworldoutcomesin pages 1-3) 6) Real-world respiratory impact after OA: “Ventilation time decreased from 14.3 to 11.1 hours per day, and respiratory hospitalizations decreased by 26%” in the year after treatment. DOI: 10.1007/s00431-024-05886-9; URL: https://doi.org/10.1007/s00431-024-05886-9 (Lavie et al., 2024). (lavie2024respiratoryoutcomesof pages 1-2) 7) Consensus guidance: 2024 European consensus update on the rational use of OA, including older/heavier patients and integration of real-world evidence; see main text and Supplementary Data. DOI: 10.1016/j.ejpn.2024.06.001; URL: https://doi.org/10.1016/j.ejpn.2024.06.001 (Kirschner et al., 2024). (kirschner20242024updateeuropean pages 6-6)

Gene/Protein annotations (HGNC) with ontology mapping

  • SMN1 (HGNC:11164): mRNA splicing via spliceosome (GO:0000398); spliceosomal snRNP assembly (GO:0000387); ribosome/translation (GO:0006412); axon (GO:0030424); Cajal/Gem bodies; cytoskeleton organization (GO:0000226). Evidence: reviews and mechanistic synthesis. (haque2024recentprogressin pages 1-2)
  • SMN2 (HGNC:11165): genetic modifier of SMN dosage; target of splicing therapies. (torri2024beyondmotorneurons pages 1-2)
  • SETX (HGNC:10759): R-loop resolution/DNA damage response (GO:0006281; concept-level for R-loops). Evidence: Brain Communications 2024. (shi2025cytoskeletondysfunctionof pages 1-3)
  • PFN2 (HGNC:8882), PLS3 (HGNC:9071), STMN1/2 (HGNC:6510/6511), MAP1B (HGNC:6830): cytoskeletal dynamics/axon growth (GO:0098930; GO:0000226). Evidence: Journal of Neurology 2025; therapeutic STMN2 augmentation. (shi2025cytoskeletondysfunctionof pages 1-3)
  • UBA1 (HGNC:12485): ubiquitination/proteostasis; muscle pathology in SMA. (glynn2025actincytoskeletondysregulation pages 21-24)

Cell type involvement (CL terms)

  • Motor neuron (CL:0000100; spinal alpha motor neuron): degeneration and axonal vulnerability. (torres2025dissectingtherolea pages 28-32)
  • Astrocyte (CL:0000127), microglia (CL:0000129), oligodendrocyte (CL:0000128), Schwann cell (CL:0000574): non-neuronal contributions to NMJ/axon pathology and neuroinflammation. (torri2024beyondmotorneurons pages 1-2)
  • Skeletal muscle fiber and fibro-adipogenic progenitors: intrinsic OXPHOS and maturation defects; NMJ abnormalities. (grandi2024characterizationofsma pages 1-2)

Anatomical locations (UBERON)

  • Spinal cord (ventral horn), peripheral motor axon, neuromuscular junction, skeletal muscle (including diaphragm), liver/other peripheral tissues (multisystem involvement). (torri2024beyondmotorneurons pages 1-2, grandi2024characterizationofsma pages 1-2)

Chemical entities (CHEBI)

  • Nusinersen (ASO), risdiplam (CHEBI:145709), onasemnogene abeparvovec (AAV9-based gene therapy), prednisolone (CHEBI:8383). (torri2024beyondmotorneurons pages 1-2, lavie2024respiratoryoutcomesof pages 1-2)

Recent developments (2023–2024 emphasis)

  • Mechanistic advances: R-loop/SETX axis in SMA-linked DNA damage (2024); autophagy–lysosome/TFEB dysregulation and reduced autophagic flux as a primary mechanism (2024); persistent muscle OXPHOS impairment and fibrosis post-therapy (2024). (shi2025cytoskeletondysfunctionof pages 1-3, rosignol2024understandinghowsmn pages 1-4, grandi2024characterizationofsma pages 1-2)
  • Therapeutic guidance and outcomes: 2024 European consensus on AAV9 gene therapy implementation; real-world registry evidence from RESTORE; respiratory cohort outcomes after OA. (kirschner20242024updateeuropean pages 6-6, servais2024realworldoutcomesin pages 1-3, lavie2024respiratoryoutcomesof pages 1-2)

References (with URLs and publication dates)

  • Sharma G et al. The SMN–ribosome interplay… Biochemical Society Transactions. 2024 Feb. URL: https://doi.org/10.1042/bst20231116 (mechanistic review). (haque2024recentprogressin pages 1-2)
  • Torri F et al. Beyond Motor Neurons… IJMS. 2024 Jul 3. URL: https://doi.org/10.3390/ijms25137311 (NMJ-focused review). (torri2024beyondmotorneurons pages 1-2)
  • Rashid S, Dimitriadi M. Autophagy in SMA… Front Cell Neurosci. 2024 Jan. URL: https://doi.org/10.3389/fncel.2023.1307636 (autophagy review). (rosignol2024understandinghowsmn pages 1-4)
  • Kannan A et al. Role of senataxin… Brain Commun. 2024 Jul. URL: https://doi.org/10.1093/braincomms/fcae239 (R-loop/SMA link). (shi2025cytoskeletondysfunctionof pages 1-3)
  • Grandi FC et al. Characterization of SMA type II muscle… JCI Insight. 2024 Sep 12. URL: https://doi.org/10.1172/jci.insight.180992 (treated muscle OXPHOS). (grandi2024characterizationofsma pages 1-2)
  • Servais L et al. Real-World Outcomes… RESTORE Registry. J Neuromuscul Dis. 2024 Jan 5 (Epub 2024-01-18). URL: https://doi.org/10.3233/jnd-230122 (OA outcomes). (servais2024realworldoutcomesin pages 1-3)
  • Lavie M et al. Respiratory outcomes after OA… Eur J Pediatr. 2024 Dec. URL: https://doi.org/10.1007/s00431-024-05886-9 (respiratory cohort). (lavie2024respiratoryoutcomesof pages 1-2)
  • Kirschner J et al. 2024 update: European consensus statement on gene therapy for SMA. EJPN. 2024 Jun. URL: https://doi.org/10.1016/j.ejpn.2024.06.001 (consensus). (kirschner20242024updateeuropean pages 6-6)

Notes on limitations and open questions

  • While SMN restoration improves outcomes, residual deficits (e.g., mitochondrial OXPHOS in muscle) suggest a need for adjunct, SMN-independent approaches (e.g., cytoskeletal stabilization, autophagy–lysosome and mitochondrial support, genome stability/R-loop targeting). (grandi2024characterizationofsma pages 1-2, shi2025cytoskeletondysfunctionof pages 1-3, rosignol2024understandinghowsmn pages 1-4)
  • The precise determinants of selective alpha-motor neuron vulnerability remain under study, including differential axonal demands, cytoskeletal dependencies, and local translation control. (shi2025cytoskeletondysfunctionof pages 1-3)

References

  1. (haque2024recentprogressin pages 1-2): Umme Sabrina Haque and Toshifumi Yokota. Recent progress in gene-targeting therapies for spinal muscular atrophy: promises and challenges. Genes, Jul 2024. URL: https://doi.org/10.3390/genes15080999, doi:10.3390/genes15080999. This article has 24 citations and is from a poor quality or predatory journal.

  2. (glynn2025actincytoskeletondysregulation pages 21-24): A Glynn. Actin cytoskeleton dysregulation in peripheral organs in spinal muscular atrophy (sma). Unknown journal, 2025.

  3. (shi2025cytoskeletondysfunctionof pages 1-3): Tianyu Shi, Zijie Zhou, Taiyang Xiang, Yinxuan Suo, Xiaoyan Shi, Yaoyao Li, Peng Zhang, Jun Dai, and Lei Sheng. Cytoskeleton dysfunction of motor neuron in spinal muscular atrophy. Journal of Neurology, Dec 2025. URL: https://doi.org/10.1007/s00415-024-12724-3, doi:10.1007/s00415-024-12724-3. This article has 11 citations and is from a domain leading peer-reviewed journal.

  4. (torri2024beyondmotorneurons pages 1-2): Francesca Torri, Michelangelo Mancuso, Gabriele Siciliano, and Giulia Ricci. Beyond motor neurons in spinal muscular atrophy: a focus on neuromuscular junction. International Journal of Molecular Sciences, 25:7311, Jul 2024. URL: https://doi.org/10.3390/ijms25137311, doi:10.3390/ijms25137311. This article has 8 citations and is from a poor quality or predatory journal.

  5. (grandi2024characterizationofsma pages 1-2): Fiorella Carla Grandi, Stéphanie Astord, Sonia Pezet, Elèna Gidaja, Sabrina Mazzucchi, Maud Chapart, Stéphane Vasseur, Kamel Mamchaoui, and Piera Smeriglio. Characterization of sma type ii skeletal muscle from treated patients shows oxphos deficiency and denervation. JCI Insight, Sep 2024. URL: https://doi.org/10.1172/jci.insight.180992, doi:10.1172/jci.insight.180992. This article has 8 citations and is from a domain leading peer-reviewed journal.

  6. (rosignol2024understandinghowsmn pages 1-4): PDI Rosignol. Understanding how smn protein regulates the autophagy-lysosome pathway in spinal muscular atrophy. Unknown journal, 2024.

  7. (torres2025dissectingtherolea pages 28-32): P Pacheco Torres. Dissecting the role of oxidative stress in spinal muscular atrophy (sma). Unknown journal, 2025.

  8. (chudakova2024insearchof pages 3-5): Daria Chudakova, Ludmila Kuzenkova, Andrey Fisenko, and Kirill Savostyanov. In search of spinal muscular atrophy disease modifiers. International Journal of Molecular Sciences, 25:11210, Oct 2024. URL: https://doi.org/10.3390/ijms252011210, doi:10.3390/ijms252011210. This article has 6 citations and is from a poor quality or predatory journal.

  9. (lavie2024respiratoryoutcomesof pages 1-2): Moran Lavie, Mika Rochman, Keren Armoni Domany, Inbal Golan Tripto, Moria Be’er, Omri Besor, Liora Sagi, Sharon Aharoni, Mira Ginsberg, Iris Noyman, and Hagit Levine. Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. European Journal of Pediatrics, Dec 2024. URL: https://doi.org/10.1007/s00431-024-05886-9, doi:10.1007/s00431-024-05886-9. This article has 5 citations and is from a peer-reviewed journal.

  10. (servais2024realworldoutcomesin pages 1-3): Laurent Servais, John W. Day, Darryl C. De Vivo, Janbernd Kirschner, Eugenio Mercuri, Francesco Muntoni, Crystal M. Proud, Perry B. Shieh, Eduardo F. Tizzano, Susana Quijano-Roy, Isabelle Desguerre, Kayoko Saito, Eric Faulkner, Kamal M. Benguerba, Dheeraj Raju, Nicole LaMarca, Rui Sun, Frederick A. Anderson, and Richard S. Finkel. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the restore registry. Journal of Neuromuscular Diseases, 11:425-442, Jan 2024. URL: https://doi.org/10.3233/jnd-230122, doi:10.3233/jnd-230122. This article has 58 citations and is from a peer-reviewed journal.

  11. (kirschner20242024updateeuropean pages 6-6): Janbernd Kirschner, Günther Bernert, Nina Butoianu, Liesbeth De Waele, Aviva Fattal-Valevski, Jana Haberlova, Teresa Moreno, Andrea Katharina Klein, Anna Kostera-Pruszczyk, Eugenio Mercuri, Susana Quijano-Roy, Thomas Sejersen, Eduardo F Tizzano, W Ludo van der Pol, Sean Wallace, Dimitrios Zafeiriou, Andreas Ziegler, Francesco Muntoni, and Laurent Servais. 2024 update: european consensus statement on gene therapy for spinal muscular atrophy. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 51:73-78, Jun 2024. URL: https://doi.org/10.1016/j.ejpn.2024.06.001, doi:10.1016/j.ejpn.2024.06.001. This article has 28 citations.